



Applicable To:

- Medicare
- Medicaid – excluding Arizona and Kentucky
- Florida CMS Health Plan

Claims and Payment Policy: Allergy Testing

Policy Number: CPP-112

Original Effective Date: 1/10/2019

Revised Effective Date(s): N/A

BACKGROUND

Allergy is the fifth leading chronic disease in the United States, and allergy and asthma affects one in five Americans. Allergy is a type I hypersensitivity response mediated by immunoglobulin E (IgE). Following exposure to an allergen which binds to IgE on mast cells and basophils, these cells release mediators such as histamine that elicit an immediate response. Manifestations of this response include cutaneous, respiratory, cardiovascular, and gastrointestinal symptoms in addition to anaphylaxis, a potentially lethal reaction. IgE-mediated clinical conditions include hypersensitivity reactions to foods, insects, drugs, and latex; allergic rhinitis; asthma; urticaria; angioedema; atopic dermatitis; and allergic bronchopulmonary aspergillosis. Allergy tests are a crucial step in the management of these conditions. Their development is due to both genetic and environmental factors.

The two most clinically utilized tests for allergy are office-based skins tests (in vivo testing) and laboratory tests that measure specific IgE antibodies (in vitro testing). Skin tests involve the introduction of an allergen extract into the skin by a prick or puncture technique or by an intradermal technique. The patient's wheal-and-flare response is immediately measured. In studies using controlled provocation challenges, the sensitivity of prick/puncture tests has been reported to be 85-87% with a specificity of 79-86%.² Intracutaneous tests are more sensitive than prick/puncture tests and are preferred for drug and venom anaphylaxis but are not recommended for food allergy testing due to potential dangers.

In vitro tests were first used in the late 1960s and were termed radioallergosorbent tests or RASTs. These tests used a gamma counter to quantify radioactively labeled IgE antibody bound to a solid-phase antigen on a paper disc. The radioactive assay has been replaced by a colorimetric assay, a fluoroimmunoassay, and a chemiluminescent assay. These assays are all calibrated against the World Health Organization 75/502 international human serum IgE reference preparation. The sensitivity of these assays compared to skin tests averages 70-75%, but it is notable that there is no gold standard for allergen-specific IgE testing by which to assess skin tests or in vitro tests. The three

enzymatic assays may not yield the same results, and IgE levels from differing assays may not be interchangeable. For this reason, it is desirable to use the same assay over time for a patient.

Skin tests are more often utilized than serologic tests for the diagnosis of allergy, but there are certain situations where skin tests are not preferable. Histamine antagonists, antidepressants, and long-term, high-dose glucocorticoid therapy affect skin test results. Skin tests should not be performed at the site of active dermatitis, severe dermatographism or topical application of corticosteroids. Other situations where serologic tests may be more appropriate include patients with a history of dangerous allergic reactions, patients who have discordance between exposure history and skin test results, and uncooperative patients or those preferring in vitro testing.

Allergen immunotherapy (known in lay parlance as allergy shots) is based on the findings of skin or serum allergy testing in combination with the clinical history. This therapy exposes patients in a controlled fashion to specific allergens with the aim of achieving symptom remission. Studies have shown that allergy immunotherapy may prevent asthma in patients with allergic rhinitis.⁶ Patients receiving immunotherapy for allergy usually experience an initial increase in specific IgE antibody levels with a subsequent decrease in these levels over time. Patients note improvement of symptoms before the levels decrease, and a decrease in specific IgE levels is not necessary for immunotherapy to be efficacious.

POSITION STATEMENT

Allergy testing

The following types of allergy testing are considered **medically necessary** and **covered** when one of the following criterion (1 through 11) are met:

1. **Epicutaneous (scratch, prick or puncture)*** when IgE-mediated reactions occur to any of the following:
 - Foods; **OR**
 - Hymenoptera (stinging insects); **OR**
 - Inhalants; **OR**
 - Specific drugs (penicillins and macromolecular agents).

* For epicutaneous and intracutaneous skin tests, evaluation of inhalant allergy may require up to 70 percutaneous tests, followed by up to 40 intracutaneous tests (typically performed with a negative percutaneous test result). Fewer tests are often required.

2. **Intradermal (intracutaneous)*** when IgE-mediated reactions occur to any of the following:
 - Foods; **OR**
 - Hymenoptera (stinging insects); **OR**
 - Inhalants; **OR**
 - Specific drugs (penicillins and macromolecular agents).

* For epicutaneous and intracutaneous skin tests, evaluation of inhalant allergy may require up to 70 percutaneous tests, followed by up to 40 intracutaneous tests (typically performed with a negative percutaneous test result). Fewer tests are often required.

3. **Skin Endpoint Titration (SET) (or intradermal dilutional testing [IDT])** to determine the starting dose for immunotherapy for members who are highly allergic to stinging insects (hymenoptera venom allergy [stinging insects]) or inhalants.

NOTE: SET should not be used in place of skin testing. It may be used to determine the starting dose for immunotherapy in highly allergic members; up to 14 titration tests may be necessary. An additional 40 antigens or 80 IDT injections may be medically necessary if any of the initial test results is positive.

4. **Skin Patch Testing** for diagnosing contact allergic dermatitis.

For testing prior to joint replacement surgery when:

- Previous surgery involving an implant with complications suspected to be caused by metal allergy; **OR**
- History of severe localized (e.g., blistering, hives, and/or extensive rash) or systemic cutaneous reaction to metals

For testing after to joint replacement surgery when:

- There is a presence of symptoms attributable to metal allergy/hypersensitivity (e.g., pain, swelling, cutaneous rash, loss of function); **OR**
- Etiology other than metal allergy/hypersensitivity (e.g., infection, mechanical failure) has been excluded

5. **Photo Patch Testing** for diagnosing photo-allergy (e.g., photo-allergic contact dermatitis).

6. **Photo Tests** for evaluating photo-sensitivity disorders.

7. **Bronchial Challenge Test** for testing with methacholine, histamine or antigens in defining asthma or airway hyperactivity when one of the following is met:

- Test is being used to identify new allergens for which skin or blood testing has not been validated; **OR**
- Skin testing is unreliable.

8. **Exercise Challenge Testing** for exercise-induced bronchospasm.

9. **Ingestion (Oral) Challenge Test** for any of the following:

- Food or other substances (i.e., metabisulfite); **OR**
- Drugs when all of the following are met:
 - History of allergy to a particular drug; **AND**
 - There is no effective alternative drug; **AND**
 - Treatment with that drug class is essential.

10. **In Vitro IgE Antibody Tests** (radioallergosorbent test [RAST], multiple radioallergosorbent test [MAST], MRT [modified RAST], VAST, fluorescent allergosorbent test [FAST], enzyme-linked immunosorbent assay [ELISA], ImmunoCAP, paper radioimmunosorbent test [PRIST], radioimmunosorbent test [RIST]) are for:

- Allergic broncho-pulmonary aspergillosis (ABPA) and certain parasitic diseases; **OR**
- Food allergy; **OR**
- Hymenoptera venom allergy (stinging insects); **OR**
- Inhalant allergy; **OR**
- Specific drugs.

Testing is medically necessary for the diagnosis of suspected IgE-mediated food or inhalant allergies for any of the following in members:

- With severe dermatographism, ichthyosis or generalized eczema; **OR**
- Who cannot be safely withdrawn from medications that interfere with skin testing (such as long-acting antihistamines, tricyclic antidepressants); **OR**
- Who have a history of a previous systemic reaction to skin testing; **OR**
- When specific IgE immunoassays are used as adjunctive testing for disease activity of allergic bronchopulmonary aspergillosis and certain parasitic diseases.

11.

Total Serum IgE for diagnostic evaluation in members with known or suspected ABPA and or hyper IgE syndrome. Lymphocyte transformation tests (LTT) (lymphocyte mitogen response test, PHE stimulation test, lymphocyte antigen response assay) may be medically necessary for evaluation of members:

- For sensitivity to beryllium;

- Are suspected of having congenital or acquired immunodeficiency diseases affecting cell-mediated immunity (e.g., severe combined immunodeficiency, common variable immunodeficiency, X-linked immunodeficiency with hyper IgM, Nijmegen breakage syndrome, reticular dysgenesis, DiGeorge syndrome, Nezelof syndrome, Wiscott-Aldrich syndrome, ataxia telangiectasia, and chronic mucocutaneous candidiasis); **OR**
- With thymoma and to predict allograft compatibility in the transplant setting; **OR**
- When performed following joint replacement surgery when the following criteria are met:
 - There is a presence of symptoms attributable to metal allergy/hypersensitivity (e.g., pain, swelling, cutaneous rash, loss of function); **AND**
 - Etiology other than metal allergy/hypersensitivity (e.g., infection, mechanical failure) has been excluded.

Lymphocyte transformation tests **are not considered medically necessary** for evaluation of persons with allergies or other hypersensitivities.

NOTE: In vitro tests may be medically necessary for the initial allergy screen in lieu of skin testing. An initial allergy screen is 12 tests; additional tests may be medically necessary if any initial test result is positive. If all test results are negative, additional testing beyond the initial allergy screen of 12 tests/allergens is not considered medically necessary.

NOTE: Units billed in excess of 120 units per day and/or 120 units per year require submission of documentation of medical necessity.

The following tests are considered **non-covered and/or excluded** due to experimental and investigational status:

- ALCAT test (Antigen Leukocyte Cellular Antibody Test, an automated food allergy test)
- Alpha gal allergy (meat allergy) testing
- Anti-Fc epsilon receptor antibodies testing
- Anti-IgE receptor antibody testing
- Body chemical analysis
- Bronchial provocation/challenge testing for common allergens (e.g., dust, ragweed)
- Candidiasis test
- Chlorinated pesticides (serum)
- Chronic Urticaria Index testing
- Clifford materials reactivity testing
- Complement (total or components); (may be appropriate in autoimmune disorders, complement component deficiencies, hereditary angioedema, vasculitis)
- Complement Antigen Testing
- Conjunctival challenge/provocation
- C-reactive protein (may be appropriate in inflammatory diseases)
- Cytokine and cytokine receptor assay
- Cytotoxic food testing (Bryans Test, ACT)
- Electrodermal acupuncture
- ELISA/ACT
- Eosinophil cationic protein (ECP) test
- Food immune complex assays (FICA)
- IgG RAST/ELISA testing
- Immune complex assay (may be appropriate in autoimmune disorders, systemic lupus erythematosus, vasculitis)
- In-vitro metal allergy testing (as known as lymphocyte transformation tests [LTT])
- Leukocyte antibodies testing
- Leukocyte histamine release test

- Lymphocytes (B or T subsets); (may be appropriate for collagen vascular disease, immune deficiency syndromes, leukemia, lymphomas)
- Lymphocyte function assay
- Lymphocyte subset counts
- Mediator release test (MRT)
- Muscle strength testing or measurement (kinesiology) after allergen ingestion
- Nasal challenge/provocation
- Ophthalmic mucous membrane tests/conjunctival challenge tests
- Prausnitz-Kustner or P-K testing -- passive cutaneous transfer test
- Provocative nasal test (also known as nasal provocation testing)
- Provocation-neutralization testing (Rinkel Test) either subcutaneously or sublingually
- Pulse test (pulse response test, reaginic pulse test)
- Rebeck skin window test
- Serum immunoglobulin A (IgA), immunoglobulin G (IgG) testing for allergy
- Sublingual provocative neutralization testing and treatment with hormones
- Testing for electromagnetic sensitivity syndrome/disorder (also known as allergy to electricity, electro-sensitivity, electrohypersensitivity, and hypersensitivity to electricity)
- Testing for multiple chemical sensitivity syndrome (also known as idiopathic environmental intolerance (IEI), clinical ecological illness, clinical ecology, environmental illness, chemical AIDS, environmental/chemical hypersensitivity disease, total allergy syndrome, cerebral allergy, 20th century disease)
- Venom blocking antibodies
- Volatile chemical panels (blood testing for chemicals).
- Tests listed in section I.A., when performed for indications not listed as medically necessary.

Allergy Immunotherapy

Allergy immunotherapy for the treatment of the IgE-mediated allergies below **is considered medically necessary and covered** when administered in a medical facility:

Allergic (extrinsic) asthma

- Dust mite atopic dermatitis
- Hymenoptera (bees, hornets, wasps, fire ants) sensitive individuals when the following are met:
 - Member has a history of systemic reaction to a Hymenoptera sting;
 - There is a presence of Hymenoptera-specific IgE demonstrated by skin testing or serum/in-vitro testing;
- Mold-induced allergic rhinitis
- Perennial rhinitis
- Seasonal allergic rhinitis or conjunctivitis when all of the following conditions are met:
 - Member has symptoms of allergic rhinitis and/or asthma after natural exposure to the allergen **OR** has a life-threatening allergy to insect stings (bees, hornets, wasps, and fire ants), **AND**
 - Member has skin test and/or serologic evidence of IgE-mediated antibody to a potent extract of the allergen, **AND**
 - Avoidance or pharmacologic therapy cannot control allergic symptoms or member has unacceptable side effects with pharmacologic therapy.

NOTE: Units billed in excess of 120 units per day and/or 120 units per year require submission of documentation of medical necessity.

In addition, rapid desensitization (e.g., rush, cluster or acute desensitization) **is considered medically necessary** when any of the following are met:

- Allergy to a particular drug that cannot be treated effectively with alternative medications; **OR**
- Insect sting (e.g., wasps, hornets, bees, fire ants) hypersensitivity (hymenoptera); **OR**

- Members with moderate to severe allergic rhinitis who need treatment during or immediately before the season of the affecting allergy.

NOTE: If a woman is contemplating pregnancy and requires initiation of allergy immunotherapy and/or it is anticipated that she will require allergy medications that may increase risk to her or the fetus, rapid desensitization is an acceptable approach.

Epinephrine kits (e.g., Ana-Kit, Epi-Pen auto-injectors) **are considered medically necessary** to prevent anaphylactic shock for individuals who have had life-threatening reactions to insect stings, foods, drugs or other allergens or have severe asthma or if needed during immunotherapy.

Aspirin Desensitization **is considered medically necessary** for aspirin sensitive persons who requiring administration of ASA or ASA-like drugs (aspirin avoidance is not possible) in the setting of:

- Chronic rhinosinusitis with nasal polyposis that is refractory to topical glucocorticoids, leukotriene modifying agents and other therapies; or
- Stable cardiovascular disease or cardiovascular risk factors requiring aspirin antiplatelet therapy; or
- The need for NSAIDS to treat chronic inflammatory conditions, such as arthritis; or
- Antiphospholipid syndromes during pregnancy; or
- Poorly controlled asthma.

The following diagnoses **are considered experimental/investigational** due to a lack of established efficacy and are considered **non-covered or excluded**:

- Angioedema
- Atopic dermatitis (cover for dust mite atopic dermatitis)
- Chronic urticaria
- Food allergy or hypersensitivity
- Intrinsic (non-allergic) asthma
- Migraine headaches
- Non-allergic vasomotor rhinitis

In addition, the following procedures **are considered experimental / investigational**:

- Acupuncture for allergies
- Allergoids (modification of allergens to reduce allergenicity)
- Aspirin desensitization for any indication not listed above
- Autogenous urine immunization (autogenous urine therapy)
- Bacterial immunotherapy
- Detoxification for allergies
- Ecology units/environmental control units/environmental chemical avoidance for multiple chemical sensitivity syndrome
- Enzyme potentiated desensitization (EPD)
- Epinephrine kits for other indications not listed above
- Helminth *Trichuris suis* therapy for allergic rhinitis
- Home administration of allergy immunotherapy
- Homeopathy for allergies
- Injection of food extracts
- Intranasal immunotherapy
- Neutralization therapy (desensitization neutralization therapy)
- Neutralizing therapy of chemical and food extracts
- Oral nystatin for the treatment of candidiasis hypersensitivity syndrome

- Peptide therapy
- Photo-inactivated extracts
- Polymerized extracts
- Poison ivy/poison oak extracts for immunotherapy in the prevention of toxicodendron (Rhus) dermatitis
- Rapid desensitization for indications not listed above
- Repository emulsion therapy
- Rhinophototherapy
- Rotational and multiple food elimination diets (e.g., rotary diversified diet)
- Sublingual drops/sublingual immunotherapy other than Oralair, Grastek and Ragwitek. (Oralair and Grastek tablets are considered medically necessary for grass pollen allergies and Ragwitek is considered medically necessary for ragweed pollen allergies.)*
- Treatments for electromagnetic sensitivity syndrome/disorder
- Ultra-low dose enzyme activated immunotherapy (low dose allergens or LDA).

NOTE: In vitro tests MAY BE medically necessary for the initial allergy screen in lieu of skin testing in certain situations (i.e. member has serious skin condition, skin tests are inconclusive). An initial allergy screen is comprised of 12 tests. Additional tests may be medically necessary if any of the initial test results are positive. If all test results are negative, additional testing beyond the initial allergy screen of 12 tests/allergens is not considered medically necessary.

NOTE: Routine allergy re-testing is NOT considered medically necessary.

Specialties **allowed** to bill for Allergy/Immunotherapy testing:

Primary Care/Family Practice
Pediatric Otolaryngologist (ENT)
Allergy/Immunotherapy
Dermatology

CODING & BILLING

ICD-10 CM codes that are **covered**:

D72.1	Eosinophilia
H10.10	Acute atopic conjunctivitis, unspecified eye
H10.11	Acute atopic conjunctivitis, right eye
H10.12	Acute atopic conjunctivitis, left eye
H10.13	Acute atopic conjunctivitis, bilateral
H10.411	Chronic giant papillary conjunctivitis, right eye
H10.412	Chronic giant papillary conjunctivitis, left eye
H10.413	Chronic giant papillary conjunctivitis, bilateral
H10.419	Chronic giant papillary conjunctivitis, unspecified eye
H10.45	Other chronic allergic conjunctivitis
H65.00	Acute serous otitis media, unspecified ear
H65.01	Acute serous otitis media, right ear
H65.02	Acute serous otitis media, left ear
H65.03	Acute serous otitis media, bilateral
H65.04	Acute serous otitis media, recurrent, right ear
H65.05	Acute serous otitis media, recurrent, left ear
H65.06	Acute serous otitis media, recurrent, bilateral
H65.07	Acute serous otitis media, recurrent, unspecified ear
H65.111	Acute and subacute allergic otitis media (mucoid) (sanguinous) (serous), right ear
H65.112	Acute and subacute allergic otitis media (mucoid) (sanguinous) (serous), left ear
H65.113	Acute and subacute allergic otitis media (mucoid) (sanguinous) (serous), bilateral
H65.114	Acute and subacute allergic otitis media (mucoid) (sanguinous) (serous), recurrent, right ear
H65.115	Acute and subacute allergic otitis media (mucoid) (sanguinous) (serous), recurrent, left ear

H65.116	Acute and subacute allergic otitis media (mucoïd) (sanguinous) (serous), recurrent, bilateral
H65.117	Acute and subacute allergic otitis media (mucoïd) (sanguinous) (serous), recurrent, unspecified ear
H65.119	Acute and subacute allergic otitis media (mucoïd) (sanguinous) (serous), unspecified ear
H65.191	Other acute nonsuppurative otitis media, right ear
H65.192	Other acute nonsuppurative otitis media, left ear
H65.193	Other acute nonsuppurative otitis media, bilateral
H65.194	Other acute nonsuppurative otitis media, recurrent, right ear
H65.195	Other acute nonsuppurative otitis media, recurrent, left ear
H65.196	Other acute nonsuppurative otitis media, recurrent, bilateral
H65.197	Other acute nonsuppurative otitis media recurrent, unspecified ear
H65.199	Other acute nonsuppurative otitis media, unspecified ear
H65.20	Chronic serous otitis media, unspecified ear
H65.21	Chronic serous otitis media, right ear
H65.22	Chronic serous otitis media, left ear
H65.23	Chronic serous otitis media, bilateral
H65.411	Chronic allergic otitis media, right ear
H65.412	Chronic allergic otitis media, left ear
H65.413	Chronic allergic otitis media, bilateral
H65.419	Chronic allergic otitis media, unspecified ear
H65.491	Other chronic nonsuppurative otitis media, right ear
H65.492	Other chronic nonsuppurative otitis media, left ear
H65.493	Other chronic nonsuppurative otitis media, bilateral
H65.499	Other chronic nonsuppurative otitis media, unspecified ear
H65.90	Unspecified nonsuppurative otitis media, unspecified ear
H65.91	Unspecified nonsuppurative otitis media, right ear
H65.92	Unspecified nonsuppurative otitis media, left ear
H65.93	Unspecified nonsuppurative otitis media, bilateral
H66.90	Otitis media, unspecified, unspecified ear
H66.91	Otitis media, unspecified, right ear
H66.92	Otitis media, unspecified, left ear
H66.93	Otitis media, unspecified, bilateral
H68.001	Unspecified Eustachian salpingitis, right ear
H68.002	Unspecified Eustachian salpingitis, left ear
H68.003	Unspecified Eustachian salpingitis, bilateral
H68.009	Unspecified Eustachian salpingitis, unspecified ear
H68.011	Acute Eustachian salpingitis, right ear
H68.012	Acute Eustachian salpingitis, left ear
H68.013	Acute Eustachian salpingitis, bilateral
H68.019	Acute Eustachian salpingitis, unspecified ear
H68.021	Chronic Eustachian salpingitis, right ear
H68.022	Chronic Eustachian salpingitis, left ear
H68.023	Chronic Eustachian salpingitis, bilateral
H68.029	Chronic Eustachian salpingitis, unspecified ear
H69.80	Other specified disorders of Eustachian tube, unspecified ear
H69.81	Other specified disorders of Eustachian tube, right ear
H69.82	Other specified disorders of Eustachian tube, left ear
H69.83	Other specified disorders of Eustachian tube, bilateral
J01.00	Acute maxillary sinusitis, unspecified
J01.01	Acute recurrent maxillary sinusitis
J01.90	Acute sinusitis, unspecified
J01.91	Acute recurrent sinusitis, unspecified
J20.9	Acute bronchitis, unspecified
J30.0	Vasomotor rhinitis
J30.1	Allergic rhinitis due to pollen
J30.2	Other seasonal allergic rhinitis
J30.5	Allergic rhinitis due to food
J30.81	Allergic rhinitis due to animal (cat) (dog) hair and dander
J30.89	Other allergic rhinitis
J30.9	Allergic rhinitis, unspecified
J31.0	Chronic rhinitis

J32.0	Chronic maxillary sinusitis
J32.9	Chronic sinusitis, unspecified
J33.0	Polyp of nasal cavity
J33.1	Polypoid sinus degeneration
J33.8	Other polyp of sinus
J33.9	Nasal polyp, unspecified
J34.81	Nasal mucositis (ulcerative)
J34.89	Other specified disorders of nose and nasal sinuses
J34.9	Unspecified disorder of nose and nasal sinuses
J35.01	Chronic tonsillitis
J35.02	Chronic adenoiditis
J35.03	Chronic tonsillitis and adenoiditis
J35.1	Hypertrophy of tonsils
J35.2	Hypertrophy of adenoids
J35.3	Hypertrophy of tonsils with hypertrophy of adenoids
J44.0	Chronic obstructive pulmonary disease with acute lower respiratory infection
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation
J44.9	Chronic obstructive pulmonary disease, unspecified
J45.20	Mild intermittent asthma, uncomplicated
J45.21	Mild intermittent asthma with (acute) exacerbation
J45.22	Mild intermittent asthma with status asthmaticus
J45.30	Mild persistent asthma, uncomplicated
J45.31	Mild persistent asthma with (acute) exacerbation
J45.32	Mild persistent asthma with status asthmaticus
J45.40	Moderate persistent asthma, uncomplicated
J45.41	Moderate persistent asthma with (acute) exacerbation
J45.42	Moderate persistent asthma with status asthmaticus
J45.50	Severe persistent asthma, uncomplicated
J45.51	Severe persistent asthma with (acute) exacerbation
J45.52	Severe persistent asthma with status asthmaticus
J45.901	Unspecified asthma with (acute) exacerbation
J45.902	Unspecified asthma with status asthmaticus
J45.909	Unspecified asthma, uncomplicated
J45.991	Cough variant asthma
J45.998	Other asthma
K20.0	Eosinophilic esophagitis
L20.0	Besnier's prurigo
L20.81	Atopic neurodermatitis
L20.82	Flexural eczema
L20.84	Intrinsic (allergic) eczema
L20.89	Other atopic dermatitis
L20.9	Atopic dermatitis, unspecified
L23.1	Allergic contact dermatitis due to adhesives
L23.5	Allergic contact dermatitis due to other chemical products
L23.6	Allergic contact dermatitis due to food in contact with the skin
L23.9	Allergic contact dermatitis, unspecified cause
L24.5	Irritant contact dermatitis due to other chemical products
L24.6	Irritant contact dermatitis due to food in contact with skin
L24.9	Irritant contact dermatitis, unspecified cause
L25.3	Unspecified contact dermatitis due to other chemical products
L25.4	Unspecified contact dermatitis due to food in contact with skin
L25.9	Unspecified contact dermatitis, unspecified cause
L27.0	Generalized skin eruption due to drugs and medicaments taken internally
L27.1	Localized skin eruption due to drugs and medicaments taken internally
L27.2	Dermatitis due to ingested food
L27.8	Dermatitis due to other substances taken internally
L27.9	Dermatitis due to unspecified substance taken internally
L29.9	Pruritus, unspecified
L30.0	Nummular dermatitis

L30.2	Cutaneous autosensitization
L30.8	Other specified dermatitis
L30.9	Dermatitis, unspecified
L50.0	Allergic urticaria
L50.1	Idiopathic urticaria
L50.3	Dermatographic urticaria
L50.6	Contact urticaria
L50.8	Other urticaria
L50.9	Urticaria, unspecified
R05	Cough
R06.00	Dyspnea, unspecified
R06.02	Shortness of breath
R06.09	Other forms of dyspnea
R06.2	Wheezing
R06.3	Periodic breathing
R06.83	Snoring
R06.89	Other abnormalities of breathing
R06.9	Unspecified abnormalities of breathing
R09.81	Nasal congestion
R09.82	Postnasal drip
R21	Rash and other nonspecific skin eruption
T36.0X5A	Adverse effect of penicillins, initial encounter
T36.1X5A	Adverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter
T36.2X5A	Adverse effect of chloramphenicol group, initial encounter
T36.3X5A	Adverse effect of macrolides, initial encounter
T36.4X5A	Adverse effect of tetracyclines, initial encounter
T36.5X5A	Adverse effect of aminoglycosides, initial encounter
T36.6X5A	Adverse effect of rifampicins, initial encounter
T36.7X5A	Adverse effect of antifungal antibiotics, systemically used, initial encounter
T36.8X5A	Adverse effect of other systemic antibiotics, initial encounter
T36.95XA	Adverse effect of unspecified systemic antibiotic, initial encounter
T37.0X5A	Adverse effect of sulfonamides, initial encounter
T37.1X5A	Adverse effect of antimycobacterial drugs, initial encounter
T37.2X5A	Adverse effect of antimalarials and drugs acting on other blood protozoa, initial encounter
T37.3X5A	Adverse effect of other antiprotozoal drugs, initial encounter
T37.4X5A	Adverse effect of anthelmintics, initial encounter
T37.5X5A	Adverse effect of antiviral drugs, initial encounter
T37.8X5A	Adverse effect of other specified systemic anti-infectives and antiparasitics, initial encounter
T37.95XA	Adverse effect of unspecified systemic anti-infective and antiparasitic, initial encounter
T38.0X5A	Adverse effect of glucocorticoids and synthetic analogues, initial encounter
T38.1X5A	Adverse effect of thyroid hormones and substitutes, initial encounter
T38.2X5A	Adverse effect of antithyroid drugs, initial encounter
T38.4X5A	Adverse effect of oral contraceptives, initial encounter
T38.5X5A	Adverse effect of other estrogens and progestogens, initial encounter
T38.6X5A	Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, initial encounter
T38.7X5A	Adverse effect of androgens and anabolic congeners, initial encounter
T38.805A	Adverse effect of unspecified hormones and synthetic substitutes, initial encounter
T38.815A	Adverse effect of anterior pituitary [adenohypophyseal] hormones, initial encounter
T38.895A	Adverse effect of other hormones and synthetic substitutes, initial encounter
T38.905A	Adverse effect of unspecified hormone antagonists, initial encounter
T38.995A	Adverse effect of other hormone antagonists, initial encounter
T39.015A	Adverse effect of aspirin, initial encounter
T39.095A	Adverse effect of salicylates, initial encounter
T39.1X5A	Adverse effect of 4-Aminophenol derivatives, initial encounter
T39.2X5A	Adverse effect of pyrazolone derivatives, initial encounter
T39.315A	Adverse effect of propionic acid derivatives, initial encounter
T39.395A	Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter
T39.4X5A	Adverse effect of antirheumatics, not elsewhere classified, initial encounter
T39.8X5A	Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, initial encounter

T39.95XA	Adverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, initial encounter
T40.0X5A	Adverse effect of opium, initial encounter
T40.2X5A	Adverse effect of other opioids, initial encounter
T40.3X5A	Adverse effect of methadone, initial encounter
T40.4X5A	Adverse effect of other synthetic narcotics, initial encounter
T40.5X5A	Adverse effect of cocaine, initial encounter
T40.605A	Adverse effect of unspecified narcotics, initial encounter
T40.695A	Adverse effect of other narcotics, initial encounter
T40.7X5A	Adverse effect of cannabis (derivatives), initial encounter
T40.905A	Adverse effect of unspecified psychodysleptics [hallucinogens], initial encounter
T40.995A	Adverse effect of other psychodysleptics [hallucinogens], initial encounter
T41.0X5A	Adverse effect of inhaled anesthetics, initial encounter
T41.1X5A	Adverse effect of intravenous anesthetics, initial encounter
T41.205A	Adverse effect of unspecified general anesthetics, initial encounter
T41.295A	Adverse effect of other general anesthetics, initial encounter
T41.3X5A	Adverse effect of local anesthetics, initial encounter
T41.45XA	Adverse effect of unspecified anesthetic, initial encounter
T41.5X5A	Adverse effect of therapeutic gases, initial encounter
T42.0X5A	Adverse effect of hydantoin derivatives, initial encounter
T42.1X5A	Adverse effect of iminostilbenes, initial encounter
T42.2X5A	Adverse effect of succinimides and oxazolidinediones, initial encounter
T42.3X5A	Adverse effect of barbiturates, initial encounter
T42.4X5A	Adverse effect of benzodiazepines, initial encounter
T42.5X5A	Adverse effect of mixed antiepileptics, initial encounter
T42.6X5A	Adverse effect of other antiepileptic and sedative-hypnotic drugs, initial encounter
T42.75XA	Adverse effect of unspecified antiepileptic and sedative-hypnotic drugs, initial encounter
T42.8X5A	Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, initial encounter
T43.015A	Adverse effect of tricyclic antidepressants, initial encounter
T43.025A	Adverse effect of tetracyclic antidepressants, initial encounter
T43.1X5A	Adverse effect of monoamine-oxidase-inhibitor antidepressants, initial encounter
T43.205A	Adverse effect of unspecified antidepressants, initial encounter
T43.215A	Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, initial encounter
T43.225A	Adverse effect of selective serotonin reuptake inhibitors, initial encounter
T43.295A	Adverse effect of other antidepressants, initial encounter
T43.3X5A	Adverse effect of phenothiazine antipsychotics and neuroleptics, initial encounter
T43.4X5A	Adverse effect of butyrophenone and thiothixene neuroleptics, initial encounter
T43.505A	Adverse effect of unspecified antipsychotics and neuroleptics, initial encounter
T43.595A	Adverse effect of other antipsychotics and neuroleptics, initial encounter
T43.605A	Adverse effect of unspecified psychostimulants, initial encounter
T43.615A	Adverse effect of caffeine, initial encounter
T43.625A	Adverse effect of amphetamines, initial encounter
T43.635A	Adverse effect of methylphenidate, initial encounter
T43.695A	Adverse effect of other psychostimulants, initial encounter
T43.8X5A	Adverse effect of other psychotropic drugs, initial encounter
T43.95XA	Adverse effect of unspecified psychotropic drug, initial encounter
T44.0X5A	Adverse effect of anticholinesterase agents, initial encounter
T44.1X5A	Adverse effect of other parasympathomimetics [cholinergics], initial encounter
T44.2X5A	Adverse effect of ganglionic blocking drugs, initial encounter
T44.3X5A	Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter
T44.4X5A	Adverse effect of predominantly alpha-adrenoreceptor agonists, initial encounter
T44.5X5A	Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter
T44.6X5A	Adverse effect of alpha-adrenoreceptor antagonists, initial encounter
T44.7X5A	Adverse effect of beta-adrenoreceptor antagonists, initial encounter
T44.8X5A	Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, initial encounter
T44.905A	Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, initial encounter
T44.995A	Adverse effect of other drug primarily affecting the autonomic nervous system, initial encounter
T45.0X5A	Adverse effect of antiallergic and antiemetic drugs, initial encounter
T45.1X5A	Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter

T45.2X5A	Adverse effect of vitamins, initial encounter
T45.3X5A	Adverse effect of enzymes, initial encounter
T45.4X5A	Adverse effect of iron and its compounds, initial encounter
T45.515A	Adverse effect of anticoagulants, initial encounter
T45.525A	Adverse effect of antithrombotic drugs, initial encounter
T45.605A	Adverse effect of unspecified fibrinolysis-affecting drugs, initial encounter
T45.615A	Adverse effect of thrombolytic drugs, initial encounter
T45.625A	Adverse effect of hemostatic drug, initial encounter
T45.695A	Adverse effect of other fibrinolysis-affecting drugs, initial encounter
T45.7X5A	Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, initial encounter
T45.8X5A	Adverse effect of other primarily systemic and hematological agents, initial encounter
T45.95XA	Adverse effect of unspecified primarily systemic and hematological agent, initial encounter
T46.0X5A	Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter
T46.1X5A	Adverse effect of calcium-channel blockers, initial encounter
T46.2X5A	Adverse effect of other antidysrhythmic drugs, initial encounter
T46.3X5A	Adverse effect of coronary vasodilators, initial encounter
T46.4X5A	Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter
T46.5X5A	Adverse effect of other antihypertensive drugs, initial encounter
T46.6X5A	Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter
T46.7X5A	Adverse effect of peripheral vasodilators, initial encounter
T46.8X5A	Adverse effect of antivaricose drugs, including sclerosing agents, initial encounter
T46.905A	Adverse effect of unspecified agents primarily affecting the cardiovascular system, initial encounter
T46.995A	Adverse effect of other agents primarily affecting the cardiovascular system, initial encounter
T47.0X5A	Adverse effect of histamine H2-receptor blockers, initial encounter
T47.1X5A	Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter
T47.2X5A	Adverse effect of stimulant laxatives, initial encounter
T47.3X5A	Adverse effect of saline and osmotic laxatives, initial encounter
T47.4X5A	Adverse effect of other laxatives, initial encounter
T47.5X5A	Adverse effect of digestants, initial encounter
T47.6X5A	Adverse effect of antidiarrheal drugs, initial encounter
T47.7X5A	Adverse effect of emetics, initial encounter
T47.8X5A	Adverse effect of other agents primarily affecting gastrointestinal system, initial encounter
T47.95XA	Adverse effect of unspecified agents primarily affecting the gastrointestinal system, initial encounter
T48.0X5A	Adverse effect of oxytocic drugs, initial encounter
T48.1X5A	Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter
T48.205A	Adverse effect of unspecified drugs acting on muscles, initial encounter
T48.295A	Adverse effect of other drugs acting on muscles, initial encounter
T48.3X5A	Adverse effect of antitussives, initial encounter
T48.4X5A	Adverse effect of expectorants, initial encounter
T48.5X5A	Adverse effect of other anti-common-cold drugs, initial encounter
T48.6X5A	Adverse effect of antiasthmatics, initial encounter
T48.905A	Adverse effect of unspecified agents primarily acting on the respiratory system, initial encounter
T48.995A	Adverse effect of other agents primarily acting on the respiratory system, initial encounter
T49.0X5A	Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, initial encounter
T49.1X5A	Adverse effect of antipruritics, initial encounter
T49.2X5A	Adverse effect of local astringents and local detergents, initial encounter
T49.3X5A	Adverse effect of emollients, demulcents and protectants, initial encounter
T49.4X5A	Adverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, initial encounter
T49.5X5A	Adverse effect of ophthalmological drugs and preparations, initial encounter
T49.6X5A	Adverse effect of otorhinolaryngological drugs and preparations, initial encounter
T49.7X5A	Adverse effect of dental drugs, topically applied, initial encounter
T49.8X5A	Adverse effect of other topical agents, initial encounter
T49.95XA	Adverse effect of unspecified topical agent, initial encounter
T50.0X5A	Adverse effect of mineralocorticoids and their antagonists, initial encounter
T50.1X5A	Adverse effect of loop [high-ceiling] diuretics, initial encounter
T50.2X5A	Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter
T50.3X5A	Adverse effect of electrolytic, caloric and water-balance agents, initial encounter
T50.4X5A	Adverse effect of drugs affecting uric acid metabolism, initial encounter
T50.5X5A	Adverse effect of appetite depressants, initial encounter
T50.6X5A	Adverse effect of antidotes and chelating agents, initial encounter

T50.7X5A	Adverse effect of analeptics and opioid receptor antagonists, initial encounter
T50.8X5A	Adverse effect of diagnostic agents, initial encounter
T50.905A	Adverse effect of unspecified drugs, medicaments and biological substances, initial encounter
T50.995A	Adverse effect of other drugs, medicaments and biological substances, initial encounter
T50.A15A	Adverse effect of pertussis vaccine, including combinations with a pertussis component, initial encounter
T50.A25A	Adverse effect of mixed bacterial vaccines without a pertussis component, initial encounter
T50.A95A	Adverse effect of other bacterial vaccines, initial encounter
T50.B15A	Adverse effect of smallpox vaccines, initial encounter
T50.B95A	Adverse effect of other viral vaccines, initial encounter
T50.Z15A	Adverse effect of immunoglobulin, initial encounter
T50.Z95A	Adverse effect of other vaccines and biological substances, initial encounter
T63.001A	Toxic effect of unspecified snake venom, accidental (unintentional), initial encounter
T63.002A	Toxic effect of unspecified snake venom, intentional self-harm, initial encounter
T63.003A	Toxic effect of unspecified snake venom, assault, initial encounter
T63.004A	Toxic effect of unspecified snake venom, undetermined, initial encounter
T63.011A	Toxic effect of rattlesnake venom, accidental (unintentional), initial encounter
T63.012A	Toxic effect of rattlesnake venom, intentional self-harm, initial encounter
T63.013A	Toxic effect of rattlesnake venom, assault, initial encounter
T63.014A	Toxic effect of rattlesnake venom, undetermined, initial encounter
T63.021A	Toxic effect of coral snake venom, accidental (unintentional), initial encounter
T63.022A	Toxic effect of coral snake venom, intentional self-harm, initial encounter
T63.023A	Toxic effect of coral snake venom, assault, initial encounter
T63.024A	Toxic effect of coral snake venom, undetermined, initial encounter
T63.031A	Toxic effect of taipan venom, accidental (unintentional), initial encounter
T63.032A	Toxic effect of taipan venom, intentional self-harm, initial encounter
T63.033A	Toxic effect of taipan venom, assault, initial encounter
T63.034A	Toxic effect of taipan venom, undetermined, initial encounter
T63.041A	Toxic effect of cobra venom, accidental (unintentional), initial encounter
T63.042A	Toxic effect of cobra venom, intentional self-harm, initial encounter
T63.043A	Toxic effect of cobra venom, assault, initial encounter
T63.044A	Toxic effect of cobra venom, undetermined, initial encounter
T63.061A	Toxic effect of venom of other North and South American snake, accidental (unintentional), initial encounter
T63.062A	Toxic effect of venom of other North and South American snake, intentional self-harm, initial encounter
T63.063A	Toxic effect of venom of other North and South American snake, assault, initial encounter
T63.064A	Toxic effect of venom of other North and South American snake, undetermined, initial encounter
T63.071A	Toxic effect of venom of other Australian snake, accidental (unintentional), initial encounter
T63.072A	Toxic effect of venom of other Australian snake, intentional self-harm, initial encounter
T63.073A	Toxic effect of venom of other Australian snake, assault, initial encounter
T63.074A	Toxic effect of venom of other Australian snake, undetermined, initial encounter
T63.081A	Toxic effect of venom of other African and Asian snake, accidental (unintentional), initial encounter
T63.082A	Toxic effect of venom of other African and Asian snake, intentional self-harm, initial encounter
T63.083A	Toxic effect of venom of other African and Asian snake, assault, initial encounter
T63.084A	Toxic effect of venom of other African and Asian snake, undetermined, initial encounter
T63.091A	Toxic effect of venom of other snake, accidental (unintentional), initial encounter
T63.092A	Toxic effect of venom of other snake, intentional self-harm, initial encounter
T63.093A	Toxic effect of venom of other snake, assault, initial encounter
T63.094A	Toxic effect of venom of other snake, undetermined, initial encounter
T63.111A	Toxic effect of venom of gila monster, accidental (unintentional), initial encounter
T63.112A	Toxic effect of venom of gila monster, intentional self-harm, initial encounter
T63.113A	Toxic effect of venom of gila monster, assault, initial encounter
T63.114A	Toxic effect of venom of gila monster, undetermined, initial encounter
T63.121A	Toxic effect of venom of other venomous lizard, accidental (unintentional), initial encounter
T63.122A	Toxic effect of venom of other venomous lizard, intentional self-harm, initial encounter
T63.123A	Toxic effect of venom of other venomous lizard, assault, initial encounter
T63.124A	Toxic effect of venom of other venomous lizard, undetermined, initial encounter
T63.191A	Toxic effect of venom of other reptiles, accidental (unintentional), initial encounter
T63.192A	Toxic effect of venom of other reptiles, intentional self-harm, initial encounter
T63.193A	Toxic effect of venom of other reptiles, assault, initial encounter
T63.194A	Toxic effect of venom of other reptiles, undetermined, initial encounter

T63.2X1A	Toxic effect of venom of scorpion, accidental (unintentional), initial encounter
T63.2X2A	Toxic effect of venom of scorpion, intentional self-harm, initial encounter
T63.2X3A	Toxic effect of venom of scorpion, assault, initial encounter
T63.2X4A	Toxic effect of venom of scorpion, undetermined, initial encounter
T63.301A	Toxic effect of unspecified spider venom, accidental (unintentional), initial encounter
T63.302A	Toxic effect of unspecified spider venom, intentional self-harm, initial encounter
T63.303A	Toxic effect of unspecified spider venom, assault, initial encounter
T63.304A	Toxic effect of unspecified spider venom, undetermined, initial encounter
T63.311A	Toxic effect of venom of blackwidow spider, accidental (unintentional), initial encounter
T63.312A	Toxic effect of venom of blackwidow spider, intentional self-harm, initial encounter
T63.313A	Toxic effect of venom of blackwidow spider, assault, initial encounter
T63.314A	Toxic effect of venom of blackwidow spider, undetermined, initial encounter
T63.321A	Toxic effect of venom of tarantula, accidental (unintentional), initial encounter
T63.322A	Toxic effect of venom of tarantula, intentional self-harm, initial encounter
T63.323A	Toxic effect of venom of tarantula, assault, initial encounter
T63.324A	Toxic effect of venom of tarantula, undetermined, initial encounter
T63.331A	Toxic effect of venom of brown recluse spider, accidental (unintentional), initial encounter
T63.332A	Toxic effect of venom of brown recluse spider, intentional self-harm, initial encounter
T63.333A	Toxic effect of venom of brown recluse spider, assault, initial encounter
T63.334A	Toxic effect of venom of brown recluse spider, undetermined, initial encounter
T63.391A	Toxic effect of venom of other spider, accidental (unintentional), initial encounter
T63.392A	Toxic effect of venom of other spider, intentional self-harm, initial encounter
T63.393A	Toxic effect of venom of other spider, assault, initial encounter
T63.394A	Toxic effect of venom of other spider, undetermined, initial encounter
T63.411A	Toxic effect of venom of centipedes and venomous millipedes, accidental (unintentional), initial encounter
T63.412A	Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, initial encounter
T63.413A	Toxic effect of venom of centipedes and venomous millipedes, assault, initial encounter
T63.414A	Toxic effect of venom of centipedes and venomous millipedes, undetermined, initial encounter
T63.421A	Toxic effect of venom of ants, accidental (unintentional), initial encounter
T63.422A	Toxic effect of venom of ants, intentional self-harm, initial encounter
T63.423A	Toxic effect of venom of ants, assault, initial encounter
T63.424A	Toxic effect of venom of ants, undetermined, initial encounter
T63.431A	Toxic effect of venom of caterpillars, accidental (unintentional), initial encounter
T63.432A	Toxic effect of venom of caterpillars, intentional self-harm, initial encounter
T63.433A	Toxic effect of venom of caterpillars, assault, initial encounter
T63.434A	Toxic effect of venom of caterpillars, undetermined, initial encounter
T63.441A	Toxic effect of venom of bees, accidental (unintentional), initial encounter
T63.442A	Toxic effect of venom of bees, intentional self-harm, initial encounter
T63.443A	Toxic effect of venom of bees, assault, initial encounter
T63.444A	Toxic effect of venom of bees, undetermined, initial encounter
T63.451A	Toxic effect of venom of hornets, accidental (unintentional), initial encounter
T63.452A	Toxic effect of venom of hornets, intentional self-harm, initial encounter
T63.453A	Toxic effect of venom of hornets, assault, initial encounter
T63.454A	Toxic effect of venom of hornets, undetermined, initial encounter
T63.461A	Toxic effect of venom of wasps, accidental (unintentional), initial encounter
T63.462A	Toxic effect of venom of wasps, intentional self-harm, initial encounter
T63.463A	Toxic effect of venom of wasps, assault, initial encounter
T63.464A	Toxic effect of venom of wasps, undetermined, initial encounter

T63.481A	Toxic effect of venom of other arthropod, accidental (unintentional), initial encounter
T63.482A	Toxic effect of venom of other arthropod, intentional self-harm, initial encounter
T63.483A	Toxic effect of venom of other arthropod, assault, initial encounter
T63.484A	Toxic effect of venom of other arthropod, undetermined, initial encounter
T63.511A	Toxic effect of contact with stingray, accidental (unintentional), initial encounter
T63.512A	Toxic effect of contact with stingray, intentional self-harm, initial encounter
T63.513A	Toxic effect of contact with stingray, assault, initial encounter
T63.514A	Toxic effect of contact with stingray, undetermined, initial encounter
T63.591A	Toxic effect of contact with other venomous fish, accidental (unintentional), initial encounter
T63.592A	Toxic effect of contact with other venomous fish, intentional self-harm, initial encounter
T63.593A	Toxic effect of contact with other venomous fish, assault, initial encounter
T63.594A	Toxic effect of contact with other venomous fish, undetermined, initial encounter
T63.611A	Toxic effect of contact with Portugese Man-o-war, accidental (unintentional), initial encounter
T63.612A	Toxic effect of contact with Portugese Man-o-war, intentional self-harm, initial encounter
T63.613A	Toxic effect of contact with Portugese Man-o-war, assault, initial encounter
T63.614A	Toxic effect of contact with Portugese Man-o-war, undetermined, initial encounter
T63.621A	Toxic effect of contact with other jellyfish, accidental (unintentional), initial encounter
T63.622A	Toxic effect of contact with other jellyfish, intentional self-harm, initial encounter
T63.623A	Toxic effect of contact with other jellyfish, assault, initial encounter
T63.624A	Toxic effect of contact with other jellyfish, undetermined, initial encounter
T63.631A	Toxic effect of contact with sea anemone, accidental (unintentional), initial encounter
T63.632A	Toxic effect of contact with sea anemone, intentional self-harm, initial encounter
T63.633A	Toxic effect of contact with sea anemone, assault, initial encounter
T63.634A	Toxic effect of contact with sea anemone, undetermined, initial encounter
T63.691A	Toxic effect of contact with other venomous marine animals, accidental (unintentional), initial encounter
T63.692A	Toxic effect of contact with other venomous marine animals, intentional self-harm, initial encounter
T63.693A	Toxic effect of contact with other venomous marine animals, assault, initial encounter
T63.694A	Toxic effect of contact with other venomous marine animals, undetermined, initial encounter
T63.711A	Toxic effect of contact with venomous marine plant, accidental (unintentional), initial encounter
T63.712A	Toxic effect of contact with venomous marine plant, intentional self-harm, initial encounter
T63.713A	Toxic effect of contact with venomous marine plant, assault, initial encounter
T63.714A	Toxic effect of contact with venomous marine plant, undetermined, initial encounter
T63.791A	Toxic effect of contact with other venomous plant, accidental (unintentional), initial encounter
T63.792A	Toxic effect of contact with other venomous plant, intentional self-harm, initial encounter
T63.793A	Toxic effect of contact with other venomous plant, assault, initial encounter
T63.794A	Toxic effect of contact with other venomous plant, undetermined, initial encounter
T63.811A	Toxic effect of contact with venomous frog, accidental (unintentional), initial encounter
T63.812A	Toxic effect of contact with venomous frog, intentional self-harm, initial encounter
T63.813A	Toxic effect of contact with venomous frog, assault, initial encounter
T63.814A	Toxic effect of contact with venomous frog, undetermined, initial encounter
T63.821A	Toxic effect of contact with venomous toad, accidental (unintentional), initial encounter
T63.822A	Toxic effect of contact with venomous toad, intentional self-harm, initial encounter
T63.823A	Toxic effect of contact with venomous toad, assault, initial encounter
T63.824A	Toxic effect of contact with venomous toad, undetermined, initial encounter
T63.831A	Toxic effect of contact with other venomous amphibian, accidental (unintentional), initial encounter

T63.832A	Toxic effect of contact with other venomous amphibian, intentional self-harm, initial encounter
T63.833A	Toxic effect of contact with other venomous amphibian, assault, initial encounter
T63.834A	Toxic effect of contact with other venomous amphibian, undetermined, initial encounter
T63.891A	Toxic effect of contact with other venomous animals, accidental (unintentional), initial encounter
T63.892A	Toxic effect of contact with other venomous animals, intentional self-harm, initial encounter
T63.893A	Toxic effect of contact with other venomous animals, assault, initial encounter
T63.894A	Toxic effect of contact with other venomous animals, undetermined, initial encounter
T63.91XA	Toxic effect of contact with unspecified venomous animal, accidental (unintentional), initial encounter
T63.92XA	Toxic effect of contact with unspecified venomous animal, intentional self-harm, initial encounter
T63.93XA	Toxic effect of contact with unspecified venomous animal, assault, initial encounter
T63.94XA	Toxic effect of contact with unspecified venomous animal, undetermined, initial encounter
T65.811A	Toxic effect of latex, accidental (unintentional), initial encounter
T65.812A	Toxic effect of latex, intentional self-harm, initial encounter
T65.813A	Toxic effect of latex, assault, initial encounter
T65.814A	Toxic effect of latex, undetermined, initial encounter
T78.00XA	Anaphylactic reaction due to unspecified food, initial encounter
T78.01XA	Anaphylactic reaction due to peanuts, initial encounter
T78.02XA	Anaphylactic reaction due to shellfish (crustaceans), initial encounter
T78.03XA	Anaphylactic reaction due to other fish, initial encounter
T78.04XA	Anaphylactic reaction due to fruits and vegetables, initial encounter
T78.05XA	Anaphylactic reaction due to tree nuts and seeds, initial encounter
T78.06XA	Anaphylactic reaction due to food additives, initial encounter
T78.07XA	Anaphylactic reaction due to milk and dairy products, initial encounter

Covered ICD-10 Diagnosis Codes

D72.1	Eosinophilia
H10.10	Acute atopic conjunctivitis, unspecified eye
H10.11	Acute atopic conjunctivitis, right eye
H10.12	Acute atopic conjunctivitis, left eye
H10.13	Acute atopic conjunctivitis, bilateral
H10.411	Chronic giant papillary conjunctivitis, right eye
H10.412	Chronic giant papillary conjunctivitis, left eye
H10.413	Chronic giant papillary conjunctivitis, bilateral
H10.419	Chronic giant papillary conjunctivitis, unspecified eye
H10.45	Other chronic allergic conjunctivitis
H65.00	Acute serous otitis media, unspecified ear
H65.01	Acute serous otitis media, right ear
H65.02	Acute serous otitis media, left ear
H65.03	Acute serous otitis media, bilateral
H65.04	Acute serous otitis media, recurrent, right ear
H65.05	Acute serous otitis media, recurrent, left ear
H65.06	Acute serous otitis media, recurrent, bilateral
H65.07	Acute serous otitis media, recurrent, unspecified ear
H65.111	Acute and subacute allergic otitis media (mucoïd) (sanguinous) (serous), right ear
H65.112	Acute and subacute allergic otitis media (mucoïd) (sanguinous) (serous), left ear
H65.113	Acute and subacute allergic otitis media (mucoïd) (sanguinous) (serous), bilateral
H65.114	Acute and subacute allergic otitis media (mucoïd) (sanguinous) (serous), recurrent, right ear
H65.115	Acute and subacute allergic otitis media (mucoïd) (sanguinous) (serous), recurrent, left ear
H65.116	Acute and subacute allergic otitis media (mucoïd) (sanguinous) (serous), recurrent, bilateral
H65.117	Acute and subacute allergic otitis media (mucoïd) (sanguinous) (serous), recurrent, unspecified ear
H65.119	Acute and subacute allergic otitis media (mucoïd) (sanguinous) (serous), unspecified ear

H65.191	Other acute nonsuppurative otitis media, right ear
H65.192	Other acute nonsuppurative otitis media, left ear
H65.193	Other acute nonsuppurative otitis media, bilateral
H65.194	Other acute nonsuppurative otitis media, recurrent, right ear
H65.195	Other acute nonsuppurative otitis media, recurrent, left ear
H65.196	Other acute nonsuppurative otitis media, recurrent, bilateral
H65.197	Other acute nonsuppurative otitis media recurrent, unspecified ear
H65.199	Other acute nonsuppurative otitis media, unspecified ear
H65.20	Chronic serous otitis media, unspecified ear
H65.21	Chronic serous otitis media, right ear
H65.22	Chronic serous otitis media, left ear
H65.23	Chronic serous otitis media, bilateral
H65.411	Chronic allergic otitis media, right ear
H65.412	Chronic allergic otitis media, left ear
H65.413	Chronic allergic otitis media, bilateral
H65.419	Chronic allergic otitis media, unspecified ear
H65.491	Other chronic nonsuppurative otitis media, right ear
H65.492	Other chronic nonsuppurative otitis media, left ear
H65.493	Other chronic nonsuppurative otitis media, bilateral
H65.499	Other chronic nonsuppurative otitis media, unspecified ear
H65.90	Unspecified nonsuppurative otitis media, unspecified ear
H65.91	Unspecified nonsuppurative otitis media, right ear
H65.92	Unspecified nonsuppurative otitis media, left ear
H65.93	Unspecified nonsuppurative otitis media, bilateral
H66.90	Otitis media, unspecified, unspecified ear
H66.91	Otitis media, unspecified, right ear
H66.92	Otitis media, unspecified, left ear
H66.93	Otitis media, unspecified, bilateral
H68.001	Unspecified Eustachian salpingitis, right ear
H68.002	Unspecified Eustachian salpingitis, left ear
H68.003	Unspecified Eustachian salpingitis, bilateral
H68.009	Unspecified Eustachian salpingitis, unspecified ear
H68.011	Acute Eustachian salpingitis, right ear
H68.012	Acute Eustachian salpingitis, left ear
H68.013	Acute Eustachian salpingitis, bilateral
H68.019	Acute Eustachian salpingitis, unspecified ear
H68.021	Chronic Eustachian salpingitis, right ear
H68.022	Chronic Eustachian salpingitis, left ear
H68.023	Chronic Eustachian salpingitis, bilateral
H68.029	Chronic Eustachian salpingitis, unspecified ear
H69.80	Other specified disorders of Eustachian tube, unspecified ear
H69.81	Other specified disorders of Eustachian tube, right ear
H69.82	Other specified disorders of Eustachian tube, left ear
H69.83	Other specified disorders of Eustachian tube, bilateral
J01.00	Acute maxillary sinusitis, unspecified
J01.01	Acute recurrent maxillary sinusitis
J01.90	Acute sinusitis, unspecified
J01.91	Acute recurrent sinusitis, unspecified
J20.9	Acute bronchitis, unspecified
J30.0	Vasomotor rhinitis
J30.1	Allergic rhinitis due to pollen
J30.2	Other seasonal allergic rhinitis
J30.5	Allergic rhinitis due to food
J30.81	Allergic rhinitis due to animal (cat) (dog) hair and dander
J30.89	Other allergic rhinitis
J30.9	Allergic rhinitis, unspecified
J31.0	Chronic rhinitis
J32.0	Chronic maxillary sinusitis
J32.9	Chronic sinusitis, unspecified
J33.0	Polyp of nasal cavity

J33.1	Polypoid sinus degeneration
J33.8	Other polyp of sinus
J33.9	Nasal polyp, unspecified
J34.81	Nasal mucositis (ulcerative)
J34.89	Other specified disorders of nose and nasal sinuses
J34.9	Unspecified disorder of nose and nasal sinuses
J35.01	Chronic tonsillitis
J35.02	Chronic adenoiditis
J35.03	Chronic tonsillitis and adenoiditis
J35.1	Hypertrophy of tonsils
J35.2	Hypertrophy of adenoids
J35.3	Hypertrophy of tonsils with hypertrophy of adenoids
J44.0	Chronic obstructive pulmonary disease with acute lower respiratory infection
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation
J44.9	Chronic obstructive pulmonary disease, unspecified
J45.20	Mild intermittent asthma, uncomplicated
J45.21	Mild intermittent asthma with (acute) exacerbation
J45.22	Mild intermittent asthma with status asthmaticus
J45.30	Mild persistent asthma, uncomplicated
J45.31	Mild persistent asthma with (acute) exacerbation
J45.32	Mild persistent asthma with status asthmaticus
J45.40	Moderate persistent asthma, uncomplicated
J45.41	Moderate persistent asthma with (acute) exacerbation
J45.42	Moderate persistent asthma with status asthmaticus
J45.50	Severe persistent asthma, uncomplicated
J45.51	Severe persistent asthma with (acute) exacerbation
J45.52	Severe persistent asthma with status asthmaticus
J45.901	Unspecified asthma with (acute) exacerbation
J45.902	Unspecified asthma with status asthmaticus
J45.909	Unspecified asthma, uncomplicated
J45.991	Cough variant asthma
J45.998	Other asthma
K20.0	Eosinophilic esophagitis
L20.0	Besnier's prurigo
L20.81	Atopic neurodermatitis
L20.82	Flexural eczema
L20.84	Intrinsic (allergic) eczema
L20.89	Other atopic dermatitis
L20.9	Atopic dermatitis, unspecified
L23.1	Allergic contact dermatitis due to adhesives
L23.5	Allergic contact dermatitis due to other chemical products
L23.6	Allergic contact dermatitis due to food in contact with the skin
L23.9	Allergic contact dermatitis, unspecified cause
L24.5	Irritant contact dermatitis due to other chemical products
L24.6	Irritant contact dermatitis due to food in contact with skin
L24.9	Irritant contact dermatitis, unspecified cause
L25.3	Unspecified contact dermatitis due to other chemical products
L25.4	Unspecified contact dermatitis due to food in contact with skin
L25.9	Unspecified contact dermatitis, unspecified cause
L27.0	Generalized skin eruption due to drugs and medicaments taken internally
L27.1	Localized skin eruption due to drugs and medicaments taken internally
L27.2	Dermatitis due to ingested food
L27.8	Dermatitis due to other substances taken internally
L27.9	Dermatitis due to unspecified substance taken internally
L29.9	Pruritus, unspecified
L30.0	Nummular dermatitis
L30.2	Cutaneous auto sensitization
L30.8	Other specified dermatitis
L30.9	Dermatitis, unspecified
L50.0	Allergic urticaria

L50.1	Idiopathic urticarial
L50.9	Urticaria, unspecified
R05	Cough
R06.00	Dyspnea, unspecified
R06.02	Shortness of breath
R06.09	Other forms of dyspnea
R06.2	Wheezing
R06.3	Periodic breathing
R06.83	Snoring
R06.89	Other abnormalities of breathing
R06.9	Unspecified abnormalities of breathing
R09.81	Nasal congestion
R09.82	Postnasal drip
R21	Rash and other nonspecific skin eruption
T36.0X5A	Adverse effect of penicillins, initial encounter
T36.1X5A	Adverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter
T36.2X5A	Adverse effect of chloramphenicol group, initial encounter
T36.3X5A	Adverse effect of macrolides, initial encounter
T36.4X5A	Adverse effect of tetracyclines, initial encounter
T36.5X5A	Adverse effect of aminoglycosides, initial encounter
T36.6X5A	Adverse effect of rifampicins, initial encounter
T36.7X5A	Adverse effect of antifungal antibiotics, systemically used, initial encounter
T36.8X5A	Adverse effect of other systemic antibiotics, initial encounter
T36.95XA	Adverse effect of unspecified systemic antibiotic, initial encounter
T37.0X5A	Adverse effect of sulfonamides, initial encounter
T36.6X5A	Adverse effect of rifampicins, initial encounter
T36.7X5A	Adverse effect of antifungal antibiotics, systemically used, initial encounter
T36.8X5A	Adverse effect of other systemic antibiotics, initial encounter
T36.95XA	Adverse effect of unspecified systemic antibiotic, initial encounter
T37.0X5A	Adverse effect of sulfonamides, initial encounter
T37.1X5A	Adverse effect of antimycobacterial drugs, initial encounter
T37.2X5A	Adverse effect of antimalarials and drugs acting on other blood protozoa, initial encounter
T37.3X5A	Adverse effect of other antiprotozoal drugs, initial encounter
T37.4X5A	Adverse effect of anthelmintics, initial encounter
T37.5X5A	Adverse effect of antiviral drugs, initial encounter
T37.8X5A	Adverse effect of other specified systemic anti-infectives and antiparasitics, initial encounter
T37.95XA	Adverse effect of unspecified systemic anti-infective and antiparasitic, initial encounter
T38.0X5A	Adverse effect of glucocorticoids and synthetic analogues, initial encounter
T38.1X5A	Adverse effect of thyroid hormones and substitutes, initial encounter
T38.2X5A	Adverse effect of antithyroid drugs, initial encounter
T38.4X5A	Adverse effect of oral contraceptives, initial encounter
T38.5X5A	Adverse effect of other estrogens and progestogens, initial encounter
T38.6X5A	Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, initial encounter
T38.7X5A	Adverse effect of androgens and anabolic congeners, initial encounter
T38.805A	Adverse effect of unspecified hormones and synthetic substitutes, initial encounter
T38.815A	Adverse effect of anterior pituitary [adenohypophyseal] hormones, initial encounter
T38.895A	Adverse effect of other hormones and synthetic substitutes, initial encounter
T38.905A	Adverse effect of unspecified hormone antagonists, initial encounter
T38.995A	Adverse effect of other hormone antagonists, initial encounter
T39.015A	Adverse effect of aspirin, initial encounter
T39.095A	Adverse effect of salicylates, initial encounter
T39.1X5A	Adverse effect of 4-Aminophenol derivatives, initial encounter
T39.2X5A	Adverse effect of pyrazolone derivatives, initial encounter

T39.315A	Adverse effect of propionic acid derivatives, initial encounter
T39.395A	Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter
T39.4X5A	Adverse effect of antirheumatics, not elsewhere classified, initial encounter
T39.8X5A	Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, initial encounter
T39.95XA	Adverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, initial encounter
T40.0X5A	Adverse effect of opium, initial encounter
T40.2X5A	Adverse effect of other opioids, initial encounter
T40.3X5A	Adverse effect of methadone, initial encounter
T40.4X5A	Adverse effect of other synthetic narcotics, initial encounter
T40.5X5A	Adverse effect of cocaine, initial encounter
T40.605A	Adverse effect of unspecified narcotics, initial encounter
T40.695A	Adverse effect of other narcotics, initial encounter
T40.7X5A	Adverse effect of cannabis (derivatives), initial encounter
T40.905A	Adverse effect of unspecified psychodysleptics [hallucinogens], initial encounter
T40.995A	Adverse effect of other psychodysleptics [hallucinogens], initial encounter
T41.0X5A	Adverse effect of inhaled anesthetics, initial encounter
T41.1X5A	Adverse effect of intravenous anesthetics, initial encounter
T41.205A	Adverse effect of unspecified general anesthetics, initial encounter
T41.295A	Adverse effect of other general anesthetics, initial encounter
T41.3X5A	Adverse effect of local anesthetics, initial encounter
T41.45XA	Adverse effect of unspecified anesthetic, initial encounter
T41.5X5A	Adverse effect of therapeutic gases, initial encounter
T42.0X5A	Adverse effect of hydantoin derivatives, initial encounter
T42.1X5A	Adverse effect of iminostilbenes, initial encounter
T42.2X5A	Adverse effect of succinimides and oxazolidinediones, initial encounter
T42.3X5A	Adverse effect of barbiturates, initial encounter
T42.4X5A	Adverse effect of benzodiazepines, initial encounter
T42.5X5A	Adverse effect of mixed antiepileptics, initial encounter
T42.6X5A	Adverse effect of other antiepileptic and sedative-hypnotic drugs, initial encounter
T42.75XA	Adverse effect of unspecified antiepileptic and sedative-hypnotic drugs, initial encounter
T42.8X5A	Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, initial encounter
T43.015A	Adverse effect of tricyclic antidepressants, initial encounter
T43.025A	Adverse effect of tetracyclic antidepressants, initial encounter
T43.1X5A	Adverse effect of monoamine-oxidase-inhibitor antidepressants, initial encounter
T43.205A	Adverse effect of unspecified antidepressants, initial encounter
T43.215A	Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, initial encounter
T43.225A	Adverse effect of selective serotonin reuptake inhibitors, initial encounter
T43.295A	Adverse effect of other antidepressants, initial encounter
T43.3X5A	Adverse effect of phenothiazine antipsychotics and neuroleptics, initial encounter
T43.4X5A	Adverse effect of butyrophenone and thiothixene neuroleptics, initial encounter
T43.505A	Adverse effect of unspecified antipsychotics and neuroleptics, initial encounter
T43.595A	Adverse effect of other antipsychotics and neuroleptics, initial encounter
T43.605A	Adverse effect of unspecified psychostimulants, initial encounter
T43.615A	Adverse effect of caffeine, initial encounter
T43.625A	Adverse effect of amphetamines, initial encounter
T43.635A	Adverse effect of methylphenidate, initial encounter
T43.695A	Adverse effect of other psychostimulants, initial encounter
T43.8X5A	Adverse effect of other psychotropic drugs, initial encounter
T43.95XA	Adverse effect of unspecified psychotropic drug, initial encounter
T44.0X5A	Adverse effect of anticholinesterase agents, initial encounter
T44.1X5A	Adverse effect of other parasympathomimetics [cholinergics], initial encounter
T44.2X5A	Adverse effect of ganglionic blocking drugs, initial encounter
T44.3X5A	Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter
T44.4X5A	Adverse effect of predominantly alpha-adrenoreceptor agonists, initial encounter
T44.5X5A	Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter
T44.6X5A	Adverse effect of alpha-adrenoreceptor antagonists, initial encounter

T44.7X5A	Adverse effect of beta-adrenoreceptor antagonists, initial encounter
T44.8X5A	Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, initial encounter
T44.905A	Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, initial encounter
T44.995A	Adverse effect of other drug primarily affecting the autonomic nervous system, initial encounter
T45.0X5A	Adverse effect of antiallergic and antiemetic drugs, initial encounter
T45.1X5A	Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter
T45.2X5A	Adverse effect of vitamins, initial encounter
T45.3X5A	Adverse effect of enzymes, initial encounter
T45.4X5A	Adverse effect of iron and its compounds, initial encounter
T45.515A	Adverse effect of anticoagulants, initial encounter
T45.525A	Adverse effect of antithrombotic drugs, initial encounter
T45.605A	Adverse effect of unspecified fibrinolysis-affecting drugs, initial encounter
T45.615A	Adverse effect of thrombolytic drugs, initial encounter
T45.625A	Adverse effect of hemostatic drug, initial encounter
T45.695A	Adverse effect of other fibrinolysis-affecting drugs, initial encounter
T45.7X5A	Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, initial encounter
T45.8X5A	Adverse effect of other primarily systemic and hematological agents, initial encounter
T45.95XA	Adverse effect of unspecified primarily systemic and hematological agent, initial encounter
T46.0X5A	Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter
T46.1X5A	Adverse effect of calcium-channel blockers, initial encounter
T46.2X5A	Adverse effect of other antidysrhythmic drugs, initial encounter
T46.3X5A	Adverse effect of coronary vasodilators, initial encounter
T46.4X5A	Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter
T46.5X5A	Adverse effect of other antihypertensive drugs, initial encounter
T46.6X5A	Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter
T46.7X5A	Adverse effect of peripheral vasodilators, initial encounter
T46.8X5A	Adverse effect of antivaricose drugs, including sclerosing agents, initial encounter
T46.905A	Adverse effect of unspecified agents primarily affecting the cardiovascular system, initial encounter
T46.995A	Adverse effect of other agents primarily affecting the cardiovascular system, initial encounter
T47.0X5A	Adverse effect of histamine H2-receptor blockers, initial encounter
T47.1X5A	Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter
T47.2X5A	Adverse effect of stimulant laxatives, initial encounter
T47.3X5A	Adverse effect of saline and osmotic laxatives, initial encounter
T47.4X5A	Adverse effect of other laxatives, initial encounter
T47.5X5A	Adverse effect of digestants, initial encounter
T47.6X5A	Adverse effect of antidiarrheal drugs, initial encounter
T47.7X5A	Adverse effect of emetics, initial encounter
T47.8X5A	Adverse effect of other agents primarily affecting gastrointestinal system, initial encounter
T47.95XA	Adverse effect of unspecified agents primarily affecting the gastrointestinal system, initial encounter
T48.0X5A	Adverse effect of oxytocic drugs, initial encounter
T48.1X5A	Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter
T48.205A	Adverse effect of unspecified drugs acting on muscles, initial encounter
T48.295A	Adverse effect of other drugs acting on muscles, initial encounter
T48.3X5A	Adverse effect of antitussives, initial encounter
T48.4X5A	Adverse effect of expectorants, initial encounter
T48.5X5A	Adverse effect of other anti-common-cold drugs, initial encounter
T48.6X5A	Adverse effect of antiasthmatics, initial encounter
T48.905A	Adverse effect of unspecified agents primarily acting on the respiratory system, initial encounter
T48.995A	Adverse effect of other agents primarily acting on the respiratory system, initial encounter
T49.0X5A	Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, initial encounter
T49.1X5A	Adverse effect of antipruritics, initial encounter
T49.2X5A	Adverse effect of local astringents and local detergents, initial encounter
T49.3X5A	Adverse effect of emollients, demulcents and protectants, initial encounter
T49.4X5A	Adverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, initial encounter
T49.5X5A	Adverse effect of ophthalmological drugs and preparations, initial encounter
T49.6X5A	Adverse effect of otorhinolaryngological drugs and preparations, initial encounter
T49.7X5A	Adverse effect of dental drugs, topically applied, initial encounter

T49.8X5A	Adverse effect of other topical agents, initial encounter
T49.95XA	Adverse effect of unspecified topical agent, initial encounter
T50.0X5A	Adverse effect of mineralocorticoids and their antagonists, initial encounter
T50.1X5A	Adverse effect of loop [high-ceiling] diuretics, initial encounter
T50.2X5A	Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter
T50.3X5A	Adverse effect of electrolytic, caloric and water-balance agents, initial encounter
T50.4X5A	Adverse effect of drugs affecting uric acid metabolism, initial encounter
T50.5X5A	Adverse effect of appetite depressants, initial encounter
T50.6X5A	Adverse effect of antidotes and chelating agents, initial encounter
T50.7X5A	Adverse effect of analeptics and opioid receptor antagonists, initial encounter
T50.8X5A	Adverse effect of diagnostic agents, initial encounter
T50.905A	Adverse effect of unspecified drugs, medicaments and biological substances, initial encounter
T50.995A	Adverse effect of other drugs, medicaments and biological substances, initial encounter
T50.A15A	Adverse effect of pertussis vaccine, including combinations with a pertussis component, initial encounter
T50.A25A	Adverse effect of mixed bacterial vaccines without a pertussis component, initial encounter
T50.A95A	Adverse effect of other bacterial vaccines, initial encounter
T50.B15A	Adverse effect of smallpox vaccines, initial encounter
T50.B95A	Adverse effect of other viral vaccines, initial encounter
T50.Z15A	Adverse effect of immunoglobulin, initial encounter
T50.Z95A	Adverse effect of other vaccines and biological substances, initial encounter
T63.001A	Toxic effect of unspecified snake venom, accidental (unintentional), initial encounter
T63.002A	Toxic effect of unspecified snake venom, intentional self-harm, initial encounter
T63.003A	Toxic effect of unspecified snake venom, assault, initial encounter
T63.004A	Toxic effect of unspecified snake venom, undetermined, initial encounter
T63.011A	Toxic effect of rattlesnake venom, accidental (unintentional), initial encounter
T63.012A	Toxic effect of rattlesnake venom, intentional self-harm, initial encounter
T63.013A	Toxic effect of rattlesnake venom, assault, initial encounter
T63.014A	Toxic effect of rattlesnake venom, undetermined, initial encounter
T63.021A	Toxic effect of coral snake venom, accidental (unintentional), initial encounter
T63.022A	Toxic effect of coral snake venom, intentional self-harm, initial encounter
T63.023A	Toxic effect of coral snake venom, assault, initial encounter
T63.024A	Toxic effect of coral snake venom, undetermined, initial encounter
T63.031A	Toxic effect of taipan venom, accidental (unintentional), initial encounter
T63.032A	Toxic effect of taipan venom, intentional self-harm, initial encounter
T63.033A	Toxic effect of taipan venom, assault, initial encounter
T63.034A	Toxic effect of taipan venom, undetermined, initial encounter
T63.041A	Toxic effect of cobra venom, accidental (unintentional), initial encounter
T63.042A	Toxic effect of cobra venom, intentional self-harm, initial encounter
T63.043A	Toxic effect of cobra venom, assault, initial encounter
T63.044A	Toxic effect of cobra venom, undetermined, initial encounter
T63.061A	Toxic effect of venom of other North and South American snake, accidental (unintentional), initial encounter
T63.062A	Toxic effect of venom of other North and South American snake, intentional self-harm, initial encounter
T63.063A	Toxic effect of venom of other North and South American snake, assault, initial encounter
T63.064A	Toxic effect of venom of other North and South American snake, undetermined, initial encounter
T63.071A	Toxic effect of venom of other Australian snake, accidental (unintentional), initial encounter
T63.072A	Toxic effect of venom of other Australian snake, intentional self-harm, initial encounter
T63.073A	Toxic effect of venom of other Australian snake, assault, initial encounter
T63.074A	Toxic effect of venom of other Australian snake, undetermined, initial encounter
T63.081A	Toxic effect of venom of other African and Asian snake, accidental (unintentional), initial encounter
T63.082A	Toxic effect of venom of other African and Asian snake, intentional self-harm, initial encounter
T63.083A	Toxic effect of venom of other African and Asian snake, assault, initial encounter
T63.084A	Toxic effect of venom of other African and Asian snake, undetermined, initial encounter
T63.091A	Toxic effect of venom of other snake, accidental (unintentional), initial encounter
T63.092A	Toxic effect of venom of other snake, intentional self-harm, initial encounter
T63.093A	Toxic effect of venom of other snake, assault, initial encounter
T63.094A	Toxic effect of venom of other snake, undetermined, initial encounter
T63.111A	Toxic effect of venom of gila monster, accidental (unintentional), initial encounter
T63.112A	Toxic effect of venom of gila monster, intentional self-harm, initial encounter
T63.113A	Toxic effect of venom of gila monster, assault, initial encounter

T63.114A	Toxic effect of venom of gila monster, undetermined, initial encounter
T63.121A	Toxic effect of venom of other venomous lizard, accidental (unintentional), initial encounter
T63.122A	Toxic effect of venom of other venomous lizard, intentional self-harm, initial encounter
T63.123A	Toxic effect of venom of other venomous lizard, assault, initial encounter
T63.124A	Toxic effect of venom of other venomous lizard, undetermined, initial encounter
T63.191A	Toxic effect of venom of other reptiles, accidental (unintentional), initial encounter
T63.192A	Toxic effect of venom of other reptiles, intentional self-harm, initial encounter
T63.193A	Toxic effect of venom of other reptiles, assault, initial encounter
T63.194A	Toxic effect of venom of other reptiles, undetermined, initial encounter
T63.2X1A	Toxic effect of venom of scorpion, accidental (unintentional), initial encounter
T63.2X2A	Toxic effect of venom of scorpion, intentional self-harm, initial encounter
T63.2X3A	Toxic effect of venom of scorpion, assault, initial encounter
T63.2X4A	Toxic effect of venom of scorpion, undetermined, initial encounter
T63.301A	Toxic effect of unspecified spider venom, accidental (unintentional), initial encounter
T63.302A	Toxic effect of unspecified spider venom, intentional self-harm, initial encounter
T63.303A	Toxic effect of unspecified spider venom, assault, initial encounter
T63.304A	Toxic effect of unspecified spider venom, undetermined, initial encounter
T63.311A	Toxic effect of venom of blackwidow spider, accidental (unintentional), initial encounter
T63.312A	Toxic effect of venom of blackwidow spider, intentional self-harm, initial encounter
T63.313A	Toxic effect of venom of blackwidow spider, assault, initial encounter
T63.314A	Toxic effect of venom of blackwidow spider, undetermined, initial encounter
T63.321A	Toxic effect of venom of tarantula, accidental (unintentional), initial encounter
T63.322A	Toxic effect of venom of tarantula, intentional self-harm, initial encounter
T63.323A	Toxic effect of venom of tarantula, assault, initial encounter
T63.324A	Toxic effect of venom of tarantula, undetermined, initial encounter
T63.331A	Toxic effect of venom of brown recluse spider, accidental (unintentional), initial encounter
T63.332A	Toxic effect of venom of brown recluse spider, intentional self-harm, initial encounter
T63.333A	Toxic effect of venom of brown recluse spider, assault, initial encounter
T63.334A	Toxic effect of venom of brown recluse spider, undetermined, initial encounter
T63.391A	Toxic effect of venom of other spider, accidental (unintentional), initial encounter
T63.392A	Toxic effect of venom of other spider, intentional self-harm, initial encounter
T63.393A	Toxic effect of venom of other spider, assault, initial encounter
T63.394A	Toxic effect of venom of other spider, undetermined, initial encounter
T63.411A	Toxic effect of venom of centipedes and venomous millipedes, accidental (unintentional), initial encounter
T63.412A	Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, initial encounter
T63.413A	Toxic effect of venom of centipedes and venomous millipedes, assault, initial encounter
T63.414A	Toxic effect of venom of centipedes and venomous millipedes, undetermined, initial encounter
T63.421A	Toxic effect of venom of ants, accidental (unintentional), initial encounter
T63.422A	Toxic effect of venom of ants, intentional self-harm, initial encounter
T63.423A	Toxic effect of venom of ants, assault, initial encounter
T63.424A	Toxic effect of venom of ants, undetermined, initial encounter
T63.431A	Toxic effect of venom of caterpillars, accidental (unintentional), initial encounter
T63.432A	Toxic effect of venom of caterpillars, intentional self-harm, initial encounter
T63.433A	Toxic effect of venom of caterpillars, assault, initial encounter
T63.434A	Toxic effect of venom of caterpillars, undetermined, initial encounter
T63.441A	Toxic effect of venom of bees, accidental (unintentional), initial encounter
T63.442A	Toxic effect of venom of bees, intentional self-harm, initial encounter
T63.443A	Toxic effect of venom of bees, assault, initial encounter
T63.444A	Toxic effect of venom of bees, undetermined, initial encounter
T63.451A	Toxic effect of venom of hornets, accidental (unintentional), initial encounter
T63.452A	Toxic effect of venom of hornets, intentional self-harm, initial encounter
T63.453A	Toxic effect of venom of hornets, assault, initial encounter
T63.454A	Toxic effect of venom of hornets, undetermined, initial encounter
T63.461A	Toxic effect of venom of wasps, accidental (unintentional), initial encounter
T63.462A	Toxic effect of venom of wasps, intentional self-harm, initial encounter
T63.463A	Toxic effect of venom of wasps, assault, initial encounter
T63.464A	Toxic effect of venom of wasps, undetermined, initial encounter
T63.481A	Toxic effect of venom of other arthropod, accidental (unintentional), initial encounter
T63.482A	Toxic effect of venom of other arthropod, intentional self-harm, initial encounter

T63.483A	Toxic effect of venom of other arthropod, assault, initial encounter
T63.484A	Toxic effect of venom of other arthropod, undetermined, initial encounter
T63.511A	Toxic effect of contact with stingray, accidental (unintentional), initial encounter
T63.512A	Toxic effect of contact with stingray, intentional self-harm, initial encounter
T63.513A	Toxic effect of contact with stingray, assault, initial encounter
T63.514A	Toxic effect of contact with stingray, undetermined, initial encounter
T63.591A	Toxic effect of contact with other venomous fish, accidental (unintentional), initial encounter
T63.592A	Toxic effect of contact with other venomous fish, intentional self-harm, initial encounter
T63.593A	Toxic effect of contact with other venomous fish, assault, initial encounter
T63.594A	Toxic effect of contact with other venomous fish, undetermined, initial encounter
T63.611A	Toxic effect of contact with Portugese Man-o-war, accidental (unintentional), initial encounter
T63.612A	Toxic effect of contact with Portugese Man-o-war, intentional self-harm, initial encounter
T63.613A	Toxic effect of contact with Portugese Man-o-war, assault, initial encounter
T63.614A	Toxic effect of contact with Portugese Man-o-war, undetermined, initial encounter
T63.621A	Toxic effect of contact with other jellyfish, accidental (unintentional), initial encounter
T63.622A	Toxic effect of contact with other jellyfish, intentional self-harm, initial encounter
T63.623A	Toxic effect of contact with other jellyfish, assault, initial encounter
T63.624A	Toxic effect of contact with other jellyfish, undetermined, initial encounter
T63.631A	Toxic effect of contact with sea anemone, accidental (unintentional), initial encounter
T63.632A	Toxic effect of contact with sea anemone, intentional self-harm, initial encounter
T63.633A	Toxic effect of contact with sea anemone, assault, initial encounter
T63.634A	Toxic effect of contact with sea anemone, undetermined, initial encounter
T63.691A	Toxic effect of contact with other venomous marine animals, accidental (unintentional), initial encounter
T63.692A	Toxic effect of contact with other venomous marine animals, intentional self-harm, initial encounter
T63.693A	Toxic effect of contact with other venomous marine animals, assault, initial encounter
T63.694A	Toxic effect of contact with other venomous marine animals, undetermined, initial encounter
T63.711A	Toxic effect of contact with venomous marine plant, accidental (unintentional), initial encounter
T63.712A	Toxic effect of contact with venomous marine plant, intentional self-harm, initial encounter
T63.713A	Toxic effect of contact with venomous marine plant, assault, initial encounter
T63.714A	Toxic effect of contact with venomous marine plant, undetermined, initial encounter
T63.791A	Toxic effect of contact with other venomous plant, accidental (unintentional), initial encounter
T63.792A	Toxic effect of contact with other venomous plant, intentional self-harm, initial encounter
T63.793A	Toxic effect of contact with other venomous plant, assault, initial encounter
T63.794A	Toxic effect of contact with other venomous plant, undetermined, initial encounter
T63.811A	Toxic effect of contact with venomous frog, accidental (unintentional), initial encounter
T63.812A	Toxic effect of contact with venomous frog, intentional self-harm, initial encounter
T63.813A	Toxic effect of contact with venomous frog, assault, initial encounter
T63.814A	Toxic effect of contact with venomous frog, undetermined, initial encounter
T63.821A	Toxic effect of contact with venomous toad, accidental (unintentional), initial encounter
T63.822A	Toxic effect of contact with venomous toad, intentional self-harm, initial encounter
T63.823A	Toxic effect of contact with venomous toad, assault, initial encounter
T63.824A	Toxic effect of contact with venomous toad, undetermined, initial encounter
T63.831A	Toxic effect of contact with other venomous amphibian, accidental (unintentional), initial encounter
T63.832A	Toxic effect of contact with other venomous amphibian, intentional self-harm, initial encounter
T63.833A	Toxic effect of contact with other venomous amphibian, assault, initial encounter
T63.834A	Toxic effect of contact with other venomous amphibian, undetermined, initial encounter
T63.891A	Toxic effect of contact with other venomous animals, accidental (unintentional), initial encounter
T63.892A	Toxic effect of contact with other venomous animals, intentional self-harm, initial encounter
T63.893A	Toxic effect of contact with other venomous animals, assault, initial encounter
T63.894A	Toxic effect of contact with other venomous animals, undetermined, initial encounter
T63.91XA	Toxic effect of contact with unspecified venomous animal, accidental (unintentional), initial encounter
T63.92XA	Toxic effect of contact with unspecified venomous animal, intentional self-harm, initial encounter
T63.93XA	Toxic effect of contact with unspecified venomous animal, assault, initial encounter
T63.94XA	Toxic effect of contact with unspecified venomous animal, undetermined, initial encounter
T65.811A	Toxic effect of latex, accidental (unintentional), initial encounter
T65.812A	Toxic effect of latex, intentional self-harm, initial encounter
T65.813A	Toxic effect of latex, assault, initial encounter
T65.814A	Toxic effect of latex, undetermined, initial encounter
T78.00XA	Anaphylactic reaction due to unspecified food, initial encounter
T78.01XA	Anaphylactic reaction due to peanuts, initial encounter

T78.02XA	Anaphylactic reaction due to shellfish (crustaceans), initial encounter
T78.03XA	Anaphylactic reaction due to other fish, initial encounter
T78.04XA	Anaphylactic reaction due to fruits and vegetables, initial encounter
T78.05XA	Anaphylactic reaction due to tree nuts and seeds, initial encounter
T78.06XA	Anaphylactic reaction due to food additives, initial encounter
T78.07XA	Anaphylactic reaction due to milk and dairy products, initial encounter
T78.08XA	Anaphylactic reaction due to eggs, initial encounter
T78.09XA	Anaphylactic reaction due to other food products, initial encounter
T78.1XXA	Other adverse food reactions, not elsewhere classified, initial encounter
T78.2XXA	Anaphylactic shock, unspecified, initial encounter
T78.3XXA	Angioneurotic edema, initial encounter
T78.40XA	Allergy, unspecified, initial encounter
T78.41XA	Arthus phenomenon, initial encounter
T78.49XA	Other allergy, initial encounter
T88.59XA	Other complications of anesthesia, initial encounter
T88.6XXA	Anaphylactic reaction due to adverse effect of correct drug or medication properly administered, initial encounter
Z00.00	Encounter for general adult medical examination without abnormal findings
Z00.01	Encounter for general adult medical examination with abnormal findings
Z00.121	Encounter for routine child health examination with abnormal findings
Z00.129	Encounter for routine child health examination without abnormal findings
Z01.82	Encounter for allergy testing
Z91.010	Allergy to peanuts
Z91.011	Allergy to milk products
Z91.012	Allergy to eggs
Z91.013	Allergy to seafood
Z91.018	Allergy to other foods
Z91.02	Food additives allergy status
Z91.030	Bee allergy status
Z91.038	Other insect allergy status
Z91.040	Latex allergy status
Z91.041	Radiographic dye allergy status
Z91.048	Other nonmedicinal substance allergy status
Z91.09	Other allergy status, other than to drugs and biological substances
D72.1	Eosinophilia
H10.10	Acute atopic conjunctivitis, unspecified eye
H10.11	Acute atopic conjunctivitis, right eye
H10.12	Acute atopic conjunctivitis, left eye
H10.13	Acute atopic conjunctivitis, bilateral
H10.411	Chronic giant papillary conjunctivitis, right eye
H10.412	Chronic giant papillary conjunctivitis, left eye
H10.413	Chronic giant papillary conjunctivitis, bilateral
H10.419	Chronic giant papillary conjunctivitis, unspecified eye
H10.45	Other chronic allergic conjunctivitis
H65.00	Acute serous otitis media, unspecified ear
H65.01	Acute serous otitis media, right ear
H65.02	Acute serous otitis media, left ear
H65.03	Acute serous otitis media, bilateral
H65.04	Acute serous otitis media, recurrent, right ear
H65.05	Acute serous otitis media, recurrent, left ear
H65.06	Acute serous otitis media, recurrent, bilateral
H65.07	Acute serous otitis media, recurrent, unspecified ear
H65.111	Acute and subacute allergic otitis media (mucoïd) (sanguinous) (serous), right ear
H65.112	Acute and subacute allergic otitis media (mucoïd) (sanguinous) (serous), left ear
H65.113	Acute and subacute allergic otitis media (mucoïd) (sanguinous) (serous), bilateral
H65.114	Acute and subacute allergic otitis media (mucoïd) (sanguinous) (serous), recurrent, right ear
H65.115	Acute and subacute allergic otitis media (mucoïd) (sanguinous) (serous), recurrent, left ear
H65.116	Acute and subacute allergic otitis media (mucoïd) (sanguinous) (serous), recurrent, bilateral
H65.117	Acute and subacute allergic otitis media (mucoïd) (sanguinous) (serous), recurrent, unspecified ear

H65.119	Acute and subacute allergic otitis media (mucoid) (sanguinous) (serous), unspecified ear
H65.191	Other acute nonsuppurative otitis media, right ear
H65.192	Other acute nonsuppurative otitis media, left ear
H65.193	Other acute nonsuppurative otitis media, bilateral
H65.194	Other acute nonsuppurative otitis media, recurrent, right ear
H65.195	Other acute nonsuppurative otitis media, recurrent, left ear
H65.196	Other acute nonsuppurative otitis media, recurrent, bilateral
H65.197	Other acute nonsuppurative otitis media recurrent, unspecified ear
H65.199	Other acute nonsuppurative otitis media, unspecified ear
H65.20	Chronic serous otitis media, unspecified ear
H65.21	Chronic serous otitis media, right ear
H65.22	Chronic serous otitis media, left ear
H65.23	Chronic serous otitis media, bilateral
H65.411	Chronic allergic otitis media, right ear
H65.412	Chronic allergic otitis media, left ear
H65.413	Chronic allergic otitis media, bilateral
H65.419	Chronic allergic otitis media, unspecified ear
H65.491	Other chronic nonsuppurative otitis media, right ear
H65.492	Other chronic nonsuppurative otitis media, left ear
H65.493	Other chronic nonsuppurative otitis media, bilateral
H65.499	Other chronic nonsuppurative otitis media, unspecified ear
H65.90	Unspecified nonsuppurative otitis media, unspecified ear
H65.91	Unspecified nonsuppurative otitis media, right ear
H65.92	Unspecified nonsuppurative otitis media, left ear
H65.93	Unspecified nonsuppurative otitis media, bilateral
H66.90	Otitis media, unspecified, unspecified ear
H66.91	Otitis media, unspecified, right ear
H66.92	Otitis media, unspecified, left ear
H66.93	Otitis media, unspecified, bilateral
H68.001	Unspecified Eustachian salpingitis, right ear
H68.002	Unspecified Eustachian salpingitis, left ear
H68.003	Unspecified Eustachian salpingitis, bilateral
H68.009	Unspecified Eustachian salpingitis, unspecified ear
H68.011	Acute Eustachian salpingitis, right ear
H68.012	Acute Eustachian salpingitis, left ear
H68.013	Acute Eustachian salpingitis, bilateral
H68.019	Acute Eustachian salpingitis, unspecified ear
H68.021	Chronic Eustachian salpingitis, right ear
H68.022	Chronic Eustachian salpingitis, left ear
H68.023	Chronic Eustachian salpingitis, bilateral
H68.029	Chronic Eustachian salpingitis, unspecified ear
H69.80	Other specified disorders of Eustachian tube, unspecified ear
H69.81	Other specified disorders of Eustachian tube, right ear
H69.82	Other specified disorders of Eustachian tube, left ear
H69.83	Other specified disorders of Eustachian tube, bilateral
J01.00	Acute maxillary sinusitis, unspecified
J01.01	Acute recurrent maxillary sinusitis
J01.90	Acute sinusitis, unspecified
J01.91	Acute recurrent sinusitis, unspecified
J20.9	Acute bronchitis, unspecified
J30.0	Vasomotor rhinitis
J30.1	Allergic rhinitis due to pollen
J30.2	Other seasonal allergic rhinitis
J30.5	Allergic rhinitis due to food
J30.81	Allergic rhinitis due to animal (cat) (dog) hair and dander
J30.89	Other allergic rhinitis
J30.9	Allergic rhinitis, unspecified
J31.0	Chronic rhinitis
J32.0	Chronic maxillary sinusitis

J32.9	Chronic sinusitis, unspecified
J33.0	Polyp of nasal cavity
J33.1	Polypoid sinus degeneration
J33.8	Other polyp of sinus
J33.9	Nasal polyp, unspecified
J34.81	Nasal mucositis (ulcerative)
J34.89	Other specified disorders of nose and nasal sinuses
J34.9	Unspecified disorder of nose and nasal sinuses
J35.01	Chronic tonsillitis
J35.02	Chronic adenoiditis
J35.03	Chronic tonsillitis and adenoiditis
J35.1	Hypertrophy of tonsils
J35.2	Hypertrophy of adenoids
J35.3	Hypertrophy of tonsils with hypertrophy of adenoids
J44.0	Chronic obstructive pulmonary disease with acute lower respiratory infection
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation
J44.9	Chronic obstructive pulmonary disease, unspecified
J45.20	Mild intermittent asthma, uncomplicated
J45.21	Mild intermittent asthma with (acute) exacerbation
J45.22	Mild intermittent asthma with status asthmaticus
J45.30	Mild persistent asthma, uncomplicated
J45.31	Mild persistent asthma with (acute) exacerbation
J45.32	Mild persistent asthma with status asthmaticus
J45.40	Moderate persistent asthma, uncomplicated
J45.41	Moderate persistent asthma with (acute) exacerbation
J45.42	Moderate persistent asthma with status asthmaticus
J45.50	Severe persistent asthma, uncomplicated
J45.51	Severe persistent asthma with (acute) exacerbation
J45.52	Severe persistent asthma with status asthmaticus
J45.901	Unspecified asthma with (acute) exacerbation
J45.902	Unspecified asthma with status asthmaticus
J45.909	Unspecified asthma, uncomplicated
J45.991	Cough variant asthma
J45.998	Other asthma
K20.0	Eosinophilic esophagitis
L20.0	Besnier's prurigo
L20.81	Atopic neurodermatitis
L20.82	Flexural eczema
L20.84	Intrinsic (allergic) eczema
L20.89	Other atopic dermatitis
L20.9	Atopic dermatitis, unspecified
L23.1	Allergic contact dermatitis due to adhesives
L23.5	Allergic contact dermatitis due to other chemical products
L23.6	Allergic contact dermatitis due to food in contact with the skin
L23.9	Allergic contact dermatitis, unspecified cause
L24.5	Irritant contact dermatitis due to other chemical products
L24.6	Irritant contact dermatitis due to food in contact with skin
L24.9	Irritant contact dermatitis, unspecified cause
L25.3	Unspecified contact dermatitis due to other chemical products
L25.4	Unspecified contact dermatitis due to food in contact with skin
L25.9	Unspecified contact dermatitis, unspecified cause
L27.0	Generalized skin eruption due to drugs and medicaments taken internally
L27.1	Localized skin eruption due to drugs and medicaments taken internally
L27.2	Dermatitis due to ingested food
L27.8	Dermatitis due to other substances taken internally
L27.9	Dermatitis due to unspecified substance taken internally
L29.9	Pruritus, unspecified
L30.0	Nummular dermatitis
L30.2	Cutaneous auto sensitization

L30.8	Other specified dermatitis
L30.9	Dermatitis, unspecified
L50.0	Allergic urticaria
L50.1	Idiopathic urticaria
L50.3	Dermatographic urticaria
L50.6	Contact urticaria
L50.8	Other urticaria
L50.9	Urticaria, unspecified
R05	Cough
R06.00	Dyspnea, unspecified
R06.02	Shortness of breath
R06.09	Other forms of dyspnea
R06.2	Wheezing
R06.3	Periodic breathing
R06.83	Snoring
R06.89	Other abnormalities of breathing
R06.9	Unspecified abnormalities of breathing
R09.81	Nasal congestion
R09.82	Postnasal drip
R21	Rash and other nonspecific skin eruption
T36.0X5A	Adverse effect of penicillins, initial encounter
T36.1X5A	Adverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter
T36.2X5A	Adverse effect of chloramphenicol group, initial encounter
T36.3X5A	Adverse effect of macrolides, initial encounter
T36.4X5A	Adverse effect of tetracyclines, initial encounter
T36.5X5A	Adverse effect of aminoglycosides, initial encounter
T36.6X5A	Adverse effect of rifampicins, initial encounter
T36.7X5A	Adverse effect of antifungal antibiotics, systemically used, initial encounter
T36.8X5A	Adverse effect of other systemic antibiotics, initial encounter
T36.95XA	Adverse effect of unspecified systemic antibiotic, initial encounter
T37.0X5A	Adverse effect of sulfonamides, initial encounter
T37.1X5A	Adverse effect of antimycobacterial drugs, initial encounter
T37.2X5A	Adverse effect of antimalarials and drugs acting on other blood protozoa, initial encounter
T37.3X5A	Adverse effect of other antiprotozoal drugs, initial encounter
T37.4X5A	Adverse effect of anthelmintics, initial encounter
T37.5X5A	Adverse effect of antiviral drugs, initial encounter
T37.8X5A	Adverse effect of other specified systemic anti-infectives and antiparasitics, initial encounter
T37.95XA	Adverse effect of unspecified systemic anti-infective and antiparasitic, initial encounter
T38.0X5A	Adverse effect of glucocorticoids and synthetic analogues, initial encounter
T38.1X5A	Adverse effect of thyroid hormones and substitutes, initial encounter
T38.2X5A	Adverse effect of antithyroid drugs, initial encounter
T38.4X5A	Adverse effect of oral contraceptives, initial encounter
T38.5X5A	Adverse effect of other estrogens and progestogens, initial encounter
T38.6X5A	Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, initial encounter
T38.7X5A	Adverse effect of androgens and anabolic congeners, initial encounter
T38.805A	Adverse effect of unspecified hormones and synthetic substitutes, initial encounter
T38.815A	Adverse effect of anterior pituitary [adenohypophyseal] hormones, initial encounter
T38.895A	Adverse effect of other hormones and synthetic substitutes, initial encounter
T38.905A	Adverse effect of unspecified hormone antagonists, initial encounter
T38.995A	Adverse effect of other hormone antagonists, initial encounter
T39.015A	Adverse effect of aspirin, initial encounter
T39.095A	Adverse effect of salicylates, initial encounter
T39.1X5A	Adverse effect of 4-Aminophenol derivatives, initial encounter
T39.2X5A	Adverse effect of pyrazolone derivatives, initial encounter
T39.315A	Adverse effect of propionic acid derivatives, initial encounter
T39.395A	Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter
T39.4X5A	Adverse effect of antirheumatics, not elsewhere classified, initial encounter
T39.8X5A	Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, initial encounter

T39.95XA	Adverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, initial encounter
T40.0X5A	Adverse effect of opium, initial encounter
T40.2X5A	Adverse effect of other opioids, initial encounter
T40.3X5A	Adverse effect of methadone, initial encounter
T40.4X5A	Adverse effect of other synthetic narcotics, initial encounter
T40.5X5A	Adverse effect of cocaine, initial encounter
T40.605A	Adverse effect of unspecified narcotics, initial encounter
T40.695A	Adverse effect of other narcotics, initial encounter
T40.7X5A	Adverse effect of cannabis (derivatives), initial encounter
T40.905A	Adverse effect of unspecified psychodysleptics [hallucinogens], initial encounter
T40.995A	Adverse effect of other psychodysleptics [hallucinogens], initial encounter
T41.0X5A	Adverse effect of inhaled anesthetics, initial encounter
T41.1X5A	Adverse effect of intravenous anesthetics, initial encounter
T41.205A	Adverse effect of unspecified general anesthetics, initial encounter
T41.295A	Adverse effect of other general anesthetics, initial encounter
T41.3X5A	Adverse effect of local anesthetics, initial encounter
T41.45XA	Adverse effect of unspecified anesthetic, initial encounter
T41.5X5A	Adverse effect of therapeutic gases, initial encounter
T42.0X5A	Adverse effect of hydantoin derivatives, initial encounter
T42.1X5A	Adverse effect of iminostilbenes, initial encounter
T42.2X5A	Adverse effect of succinimides and oxazolinediones, initial encounter
T42.3X5A	Adverse effect of barbiturates, initial encounter
T42.4X5A	Adverse effect of benzodiazepines, initial encounter
T42.5X5A	Adverse effect of mixed antiepileptics, initial encounter
T42.6X5A	Adverse effect of other antiepileptic and sedative-hypnotic drugs, initial encounter
T42.75XA	Adverse effect of unspecified antiepileptic and sedative-hypnotic drugs, initial encounter
T42.8X5A	Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, initial encounter
T43.015A	Adverse effect of tricyclic antidepressants, initial encounter
T43.025A	Adverse effect of tetracyclic antidepressants, initial encounter
T43.1X5A	Adverse effect of monoamine-oxidase-inhibitor antidepressants, initial encounter
T43.205A	Adverse effect of unspecified antidepressants, initial encounter
T43.215A	Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, initial encounter
T43.225A	Adverse effect of selective serotonin reuptake inhibitors, initial encounter
T43.295A	Adverse effect of other antidepressants, initial encounter
T43.3X5A	Adverse effect of phenothiazine antipsychotics and neuroleptics, initial encounter
T43.4X5A	Adverse effect of butyrophenone and thiothixene neuroleptics, initial encounter
T43.505A	Adverse effect of unspecified antipsychotics and neuroleptics, initial encounter
T43.595A	Adverse effect of other antipsychotics and neuroleptics, initial encounter
T43.605A	Adverse effect of unspecified psychostimulants, initial encounter
T43.615A	Adverse effect of caffeine, initial encounter
T43.625A	Adverse effect of amphetamines, initial encounter
T43.635A	Adverse effect of methylphenidate, initial encounter
T43.695A	Adverse effect of other psychostimulants, initial encounter
T43.8X5A	Adverse effect of other psychotropic drugs, initial encounter
T43.95XA	Adverse effect of unspecified psychotropic drug, initial encounter
T44.0X5A	Adverse effect of anticholinesterase agents, initial encounter
T44.1X5A	Adverse effect of other parasympathomimetics [cholinergics], initial encounter
T44.2X5A	Adverse effect of ganglionic blocking drugs, initial encounter
T44.3X5A	Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter
T44.4X5A	Adverse effect of predominantly alpha-adrenoreceptor agonists, initial encounter
T44.5X5A	Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter
T44.6X5A	Adverse effect of alpha-adrenoreceptor antagonists, initial encounter
T44.7X5A	Adverse effect of beta-adrenoreceptor antagonists, initial encounter
T44.8X5A	Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, initial encounter
T44.905A	Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, initial encounter
T44.995A	Adverse effect of other drug primarily affecting the autonomic nervous system, initial encounter
T45.0X5A	Adverse effect of anti-allergic and antiemetic drugs, initial encounter
T45.1X5A	Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter

T45.2X5A	Adverse effect of vitamins, initial encounter
T45.3X5A	Adverse effect of enzymes, initial encounter
T45.4X5A	Adverse effect of iron and its compounds, initial encounter
T45.515A	Adverse effect of anticoagulants, initial encounter
T45.525A	Adverse effect of antithrombotic drugs, initial encounter
T45.605A	Adverse effect of unspecified fibrinolysis-affecting drugs, initial encounter
T45.615A	Adverse effect of thrombolytic drugs, initial encounter
T45.625A	Adverse effect of hemostatic drug, initial encounter
T45.695A	Adverse effect of other fibrinolysis-affecting drugs, initial encounter
T45.7X5A	Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, initial encounter
T45.8X5A	Adverse effect of other primarily systemic and hematological agents, initial encounter
T45.95XA	Adverse effect of unspecified primarily systemic and hematological agent, initial encounter
T46.0X5A	Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter
T46.1X5A	Adverse effect of calcium-channel blockers, initial encounter
T46.2X5A	Adverse effect of other antidysrhythmic drugs, initial encounter
T46.3X5A	Adverse effect of coronary vasodilators, initial encounter
T46.4X5A	Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter
T46.5X5A	Adverse effect of other antihypertensive drugs, initial encounter
T46.6X5A	Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter
T46.7X5A	Adverse effect of peripheral vasodilators, initial encounter
T46.8X5A	Adverse effect of antivaricose drugs, including sclerosing agents, initial encounter
T46.905A	Adverse effect of unspecified agents primarily affecting the cardiovascular system, initial encounter
T46.995A	Adverse effect of other agents primarily affecting the cardiovascular system, initial encounter
T47.0X5A	Adverse effect of histamine H2-receptor blockers, initial encounter
T47.1X5A	Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter
T47.2X5A	Adverse effect of stimulant laxatives, initial encounter
T47.3X5A	Adverse effect of saline and osmotic laxatives, initial encounter
T47.4X5A	Adverse effect of other laxatives, initial encounter
T47.5X5A	Adverse effect of digestants, initial encounter
T47.6X5A	Adverse effect of antidiarrheal drugs, initial encounter
T47.7X5A	Adverse effect of emetics, initial encounter
T47.8X5A	Adverse effect of other agents primarily affecting gastrointestinal system, initial encounter
T47.95XA	Adverse effect of unspecified agents primarily affecting the gastrointestinal system, initial encounter
T48.0X5A	Adverse effect of oxytocic drugs, initial encounter
T48.1X5A	Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter
T48.205A	Adverse effect of unspecified drugs acting on muscles, initial encounter
T48.295A	Adverse effect of other drugs acting on muscles, initial encounter
T48.3X5A	Adverse effect of antitussives, initial encounter
T48.4X5A	Adverse effect of expectorants, initial encounter
T48.5X5A	Adverse effect of other anti-common-cold drugs, initial encounter
T48.6X5A	Adverse effect of antiasthmatics, initial encounter
T48.905A	Adverse effect of unspecified agents primarily acting on the respiratory system, initial encounter
T48.995A	Adverse effect of other agents primarily acting on the respiratory system, initial encounter
T49.0X5A	Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, initial encounter
T49.1X5A	Adverse effect of antipruritics, initial encounter
T49.2X5A	Adverse effect of local astringents and local detergents, initial encounter
T49.3X5A	Adverse effect of emollients, demulcents and protectants, initial encounter
T49.4X5A	Adverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, initial encounter
T49.5X5A	Adverse effect of ophthalmological drugs and preparations, initial encounter
T49.6X5A	Adverse effect of otorhinolaryngological drugs and preparations, initial encounter
T49.7X5A	Adverse effect of dental drugs, topically applied, initial encounter
T49.8X5A	Adverse effect of other topical agents, initial encounter
T49.95XA	Adverse effect of unspecified topical agent, initial encounter
T50.0X5A	Adverse effect of mineralocorticoids and their antagonists, initial encounter
T50.1X5A	Adverse effect of loop [high-ceiling] diuretics, initial encounter
T50.2X5A	Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter
T50.3X5A	Adverse effect of electrolytic, caloric and water-balance agents, initial encounter
T50.4X5A	Adverse effect of drugs affecting uric acid metabolism, initial encounter

T50.5X5A	Adverse effect of appetite depressants, initial encounter
T50.6X5A	Adverse effect of antidotes and chelating agents, initial encounter
T50.7X5A	Adverse effect of analeptics and opioid receptor antagonists, initial encounter
T50.8X5A	Adverse effect of diagnostic agents, initial encounter
T50.905A	Adverse effect of unspecified drugs, medicaments and biological substances, initial encounter
T50.995A	Adverse effect of other drugs, medicaments and biological substances, initial encounter
T50.A15A	Adverse effect of pertussis vaccine, including combinations with a pertussis component, initial encounter
T50.A25A	Adverse effect of mixed bacterial vaccines without a pertussis component, initial encounter
T50.A95A	Adverse effect of other bacterial vaccines, initial encounter
T50.B15A	Adverse effect of smallpox vaccines, initial encounter
T50.B95A	Adverse effect of other viral vaccines, initial encounter
T50.Z15A	Adverse effect of immunoglobulin, initial encounter
T50.Z95A	Adverse effect of other vaccines and biological substances, initial encounter
T63.001A	Toxic effect of unspecified snake venom, accidental (unintentional), initial encounter
T63.002A	Toxic effect of unspecified snake venom, intentional self-harm, initial encounter
T63.003A	Toxic effect of unspecified snake venom, assault, initial encounter
T63.004A	Toxic effect of unspecified snake venom, undetermined, initial encounter
T63.011A	Toxic effect of rattlesnake venom, accidental (unintentional), initial encounter
T63.012A	Toxic effect of rattlesnake venom, intentional self-harm, initial encounter
T63.013A	Toxic effect of rattlesnake venom, assault, initial encounter
T63.014A	Toxic effect of rattlesnake venom, undetermined, initial encounter
T63.021A	Toxic effect of coral snake venom, accidental (unintentional), initial encounter
T63.022A	Toxic effect of coral snake venom, intentional self-harm, initial encounter
T63.023A	Toxic effect of coral snake venom, assault, initial encounter
T63.024A	Toxic effect of coral snake venom, undetermined, initial encounter
T63.031A	Toxic effect of taipan venom, accidental (unintentional), initial encounter
T63.032A	Toxic effect of taipan venom, intentional self-harm, initial encounter
T63.033A	Toxic effect of taipan venom, assault, initial encounter
T63.034A	Toxic effect of taipan venom, undetermined, initial encounter
T63.041A	Toxic effect of cobra venom, accidental (unintentional), initial encounter
T63.042A	Toxic effect of cobra venom, intentional self-harm, initial encounter
T63.043A	Toxic effect of cobra venom, assault, initial encounter
T63.044A	Toxic effect of cobra venom, undetermined, initial encounter
T63.061A	Toxic effect of venom of other North and South American snake, accidental (unintentional), initial encounter
T63.062A	Toxic effect of venom of other North and South American snake, intentional self-harm, initial encounter
T63.063A	Toxic effect of venom of other North and South American snake, assault, initial encounter
T63.064A	Toxic effect of venom of other North and South American snake, undetermined, initial encounter
T63.071A	Toxic effect of venom of other Australian snake, accidental (unintentional), initial encounter
T63.072A	Toxic effect of venom of other Australian snake, intentional self-harm, initial encounter
T63.073A	Toxic effect of venom of other Australian snake, assault, initial encounter
T63.074A	Toxic effect of venom of other Australian snake, undetermined, initial encounter
T63.081A	Toxic effect of venom of other African and Asian snake, accidental (unintentional), initial encounter
T63.082A	Toxic effect of venom of other African and Asian snake, intentional self-harm, initial encounter
T63.083A	Toxic effect of venom of other African and Asian snake, assault, initial encounter
T63.084A	Toxic effect of venom of other African and Asian snake, undetermined, initial encounter
T63.091A	Toxic effect of venom of other snake, accidental (unintentional), initial encounter
T63.092A	Toxic effect of venom of other snake, intentional self-harm, initial encounter
T63.093A	Toxic effect of venom of other snake, assault, initial encounter
T63.094A	Toxic effect of venom of other snake, undetermined, initial encounter
T63.111A	Toxic effect of venom of gila monster, accidental (unintentional), initial encounter
T63.112A	Toxic effect of venom of gila monster, intentional self-harm, initial encounter
T63.113A	Toxic effect of venom of gila monster, assault, initial encounter
T63.114A	Toxic effect of venom of gila monster, undetermined, initial encounter
T63.121A	Toxic effect of venom of other venomous lizard, accidental (unintentional), initial encounter
T63.122A	Toxic effect of venom of other venomous lizard, intentional self-harm, initial encounter
T63.123A	Toxic effect of venom of other venomous lizard, assault, initial encounter
T63.124A	Toxic effect of venom of other venomous lizard, undetermined, initial encounter
T63.191A	Toxic effect of venom of other reptiles, accidental (unintentional), initial encounter
T63.192A	Toxic effect of venom of other reptiles, intentional self-harm, initial encounter

T63.193A	Toxic effect of venom of other reptiles, assault, initial encounter
T63.194A	Toxic effect of venom of other reptiles, undetermined, initial encounter
T63.2X1A	Toxic effect of venom of scorpion, accidental (unintentional), initial encounter
T63.2X2A	Toxic effect of venom of scorpion, intentional self-harm, initial encounter
T63.2X3A	Toxic effect of venom of scorpion, assault, initial encounter
T63.2X4A	Toxic effect of venom of scorpion, undetermined, initial encounter
T63.301A	Toxic effect of unspecified spider venom, accidental (unintentional), initial encounter
T63.302A	Toxic effect of unspecified spider venom, intentional self-harm, initial encounter
T63.303A	Toxic effect of unspecified spider venom, assault, initial encounter
T63.304A	Toxic effect of unspecified spider venom, undetermined, initial encounter
T63.311A	Toxic effect of venom of blackwidow spider, accidental (unintentional), initial encounter
T63.312A	Toxic effect of venom of blackwidow spider, intentional self-harm, initial encounter
T63.313A	Toxic effect of venom of blackwidow spider, assault, initial encounter
T63.314A	Toxic effect of venom of blackwidow spider, undetermined, initial encounter
T63.321A	Toxic effect of venom of tarantula, accidental (unintentional), initial encounter
T63.322A	Toxic effect of venom of tarantula, intentional self-harm, initial encounter
T63.323A	Toxic effect of venom of tarantula, assault, initial encounter
T63.324A	Toxic effect of venom of tarantula, undetermined, initial encounter
T63.331A	Toxic effect of venom of brown recluse spider, accidental (unintentional), initial encounter
T63.332A	Toxic effect of venom of brown recluse spider, intentional self-harm, initial encounter
T63.333A	Toxic effect of venom of brown recluse spider, assault, initial encounter
T63.334A	Toxic effect of venom of brown recluse spider, undetermined, initial encounter
T63.391A	Toxic effect of venom of other spider, accidental (unintentional), initial encounter
T63.392A	Toxic effect of venom of other spider, intentional self-harm, initial encounter
T63.393A	Toxic effect of venom of other spider, assault, initial encounter
T63.394A	Toxic effect of venom of other spider, undetermined, initial encounter
T63.411A	Toxic effect of venom of centipedes and venomous millipedes, accidental (unintentional), initial encounter
T63.412A	Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, initial encounter
T63.413A	Toxic effect of venom of centipedes and venomous millipedes, assault, initial encounter
T63.414A	Toxic effect of venom of centipedes and venomous millipedes, undetermined, initial encounter
T63.421A	Toxic effect of venom of ants, accidental (unintentional), initial encounter
T63.422A	Toxic effect of venom of ants, intentional self-harm, initial encounter
T63.423A	Toxic effect of venom of ants, assault, initial encounter
T63.424A	Toxic effect of venom of ants, undetermined, initial encounter
T63.431A	Toxic effect of venom of caterpillars, accidental (unintentional), initial encounter
T63.432A	Toxic effect of venom of caterpillars, intentional self-harm, initial encounter
T63.433A	Toxic effect of venom of caterpillars, assault, initial encounter
T63.434A	Toxic effect of venom of caterpillars, undetermined, initial encounter
T63.441A	Toxic effect of venom of bees, accidental (unintentional), initial encounter
T63.442A	Toxic effect of venom of bees, intentional self-harm, initial encounter
T63.443A	Toxic effect of venom of bees, assault, initial encounter
T63.444A	Toxic effect of venom of bees, undetermined, initial encounter
T63.451A	Toxic effect of venom of hornets, accidental (unintentional), initial encounter
T63.452A	Toxic effect of venom of hornets, intentional self-harm, initial encounter
T63.453A	Toxic effect of venom of hornets, assault, initial encounter
T63.454A	Toxic effect of venom of hornets, undetermined, initial encounter
T63.461A	Toxic effect of venom of wasps, accidental (unintentional), initial encounter
T63.462A	Toxic effect of venom of wasps, intentional self-harm, initial encounter
T63.463A	Toxic effect of venom of wasps, assault, initial encounter

T63.464A	Toxic effect of venom of wasps, undetermined, initial encounter
T63.481A	Toxic effect of venom of other arthropod, accidental (unintentional), initial encounter
T63.482A	Toxic effect of venom of other arthropod, intentional self-harm, initial encounter
T63.483A	Toxic effect of venom of other arthropod, assault, initial encounter
T63.484A	Toxic effect of venom of other arthropod, undetermined, initial encounter
T63.511A	Toxic effect of contact with stingray, accidental (unintentional), initial encounter
T63.512A	Toxic effect of contact with stingray, intentional self-harm, initial encounter
T63.513A	Toxic effect of contact with stingray, assault, initial encounter
T63.514A	Toxic effect of contact with stingray, undetermined, initial encounter
T63.591A	Toxic effect of contact with other venomous fish, accidental (unintentional), initial encounter
T63.592A	Toxic effect of contact with other venomous fish, intentional self-harm, initial encounter
T63.593A	Toxic effect of contact with other venomous fish, assault, initial encounter
T63.594A	Toxic effect of contact with other venomous fish, undetermined, initial encounter
T63.611A	Toxic effect of contact with Portugese Man-o-war, accidental (unintentional), initial encounter
T63.612A	Toxic effect of contact with Portugese Man-o-war, intentional self-harm, initial encounter
T63.613A	Toxic effect of contact with Portugese Man-o-war, assault, initial encounter
T63.614A	Toxic effect of contact with Portugese Man-o-war, undetermined, initial encounter
T63.621A	Toxic effect of contact with other jellyfish, accidental (unintentional), initial encounter
T63.622A	Toxic effect of contact with other jellyfish, intentional self-harm, initial encounter
T63.623A	Toxic effect of contact with other jellyfish, assault, initial encounter
T63.624A	Toxic effect of contact with other jellyfish, undetermined, initial encounter
T63.631A	Toxic effect of contact with sea anemone, accidental (unintentional), initial encounter
T63.632A	Toxic effect of contact with sea anemone, intentional self-harm, initial encounter
T63.633A	Toxic effect of contact with sea anemone, assault, initial encounter
T63.634A	Toxic effect of contact with sea anemone, undetermined, initial encounter
T63.691A	Toxic effect of contact with other venomous marine animals, accidental (unintentional), initial encounter
T63.692A	Toxic effect of contact with other venomous marine animals, intentional self-harm, initial encounter
T63.693A	Toxic effect of contact with other venomous marine animals, assault, initial encounter
T63.694A	Toxic effect of contact with other venomous marine animals, undetermined, initial encounter
T63.711A	Toxic effect of contact with venomous marine plant, accidental (unintentional), initial encounter
T63.712A	Toxic effect of contact with venomous marine plant, intentional self-harm, initial encounter
T63.713A	Toxic effect of contact with venomous marine plant, assault, initial encounter
T63.714A	Toxic effect of contact with venomous marine plant, undetermined, initial encounter
T63.791A	Toxic effect of contact with other venomous plant, accidental (unintentional), initial encounter
T63.792A	Toxic effect of contact with other venomous plant, intentional self-harm, initial encounter
T63.793A	Toxic effect of contact with other venomous plant, assault, initial encounter
T63.794A	Toxic effect of contact with other venomous plant, undetermined, initial encounter
T63.811A	Toxic effect of contact with venomous frog, accidental (unintentional), initial encounter
T63.812A	Toxic effect of contact with venomous frog, intentional self-harm, initial encounter
T63.813A	Toxic effect of contact with venomous frog, assault, initial encounter
T63.814A	Toxic effect of contact with venomous frog, undetermined, initial encounter
T63.821A	Toxic effect of contact with venomous toad, accidental (unintentional), initial encounter
T63.822A	Toxic effect of contact with venomous toad, intentional self-harm, initial encounter
T63.823A	Toxic effect of contact with venomous toad, assault, initial encounter
T63.824A	Toxic effect of contact with venomous toad, undetermined, initial encounter
T63.831A	Toxic effect of contact with other venomous amphibian, accidental (unintentional), initial encounter

T63.832A	Toxic effect of contact with other venomous amphibian, intentional self-harm, initial encounter
T63.833A	Toxic effect of contact with other venomous amphibian, assault, initial encounter
T63.834A	Toxic effect of contact with other venomous amphibian, undetermined, initial encounter
T63.891A	Toxic effect of contact with other venomous animals, accidental (unintentional), initial encounter
T63.892A	Toxic effect of contact with other venomous animals, intentional self-harm, initial encounter
T63.893A	Toxic effect of contact with other venomous animals, assault, initial encounter
T63.894A	Toxic effect of contact with other venomous animals, undetermined, initial encounter
T63.91XA	Toxic effect of contact with unspecified venomous animal, accidental (unintentional), initial encounter
T63.92XA	Toxic effect of contact with unspecified venomous animal, intentional self-harm, initial encounter
T63.93XA	Toxic effect of contact with unspecified venomous animal, assault, initial encounter
T63.94XA	Toxic effect of contact with unspecified venomous animal, undetermined, initial encounter
T65.811A	Toxic effect of latex, accidental (unintentional), initial encounter
T65.812A	Toxic effect of latex, intentional self-harm, initial encounter
T65.813A	Toxic effect of latex, assault, initial encounter
T65.814A	Toxic effect of latex, undetermined, initial encounter
T78.00XA	Anaphylactic reaction due to unspecified food, initial encounter
T78.01XA	Anaphylactic reaction due to peanuts, initial encounter
T78.02XA	Anaphylactic reaction due to shellfish (crustaceans), initial encounter
T78.03XA	Anaphylactic reaction due to other fish, initial encounter
T78.04XA	Anaphylactic reaction due to fruits and vegetables, initial encounter
T78.05XA	Anaphylactic reaction due to tree nuts and seeds, initial encounter
T78.06XA	Anaphylactic reaction due to food additives, initial encounter
T78.07XA	Anaphylactic reaction due to milk and dairy products, initial encounter
T78.08XA	Anaphylactic reaction due to eggs, initial encounter
T78.09XA	Anaphylactic reaction due to other food products, initial encounter
T78.1XXA	Other adverse food reactions, not elsewhere classified, initial encounter
T78.2XXA	Anaphylactic shock, unspecified, initial encounter
T78.3XXA	Angioneurotic edema, initial encounter
T78.40XA	Allergy, unspecified, initial encounter
T78.41XA	Arthus phenomenon, initial encounter
T78.49XA	Other allergy, initial encounter
T88.59XA	Other complications of anesthesia, initial encounter
T88.6XXA	Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, initial encounter
Z00.00	Encounter for general adult medical examination without abnormal findings
Z00.01	Encounter for general adult medical examination with abnormal findings
Z00.121	Encounter for routine child health examination with abnormal findings
Z00.129	Encounter for routine child health examination without abnormal findings
Z01.82	Encounter for allergy testing
Z91.010	Allergy to peanuts
Z91.011	Allergy to milk products
Z91.012	Allergy to eggs
Z91.013	Allergy to seafood
Z91.018	Allergy to other foods
Z91.02	Food additives allergy status
Z91.030	Bee allergy status
Z91.038	Other insect allergy status

Z91.040	Latex allergy status
Z91.041	Radiographic dye allergy status
Z91.048	Other nonmedicinal substance allergy status
Z91.09	Other allergy status, other than to drugs and biological substances

CPT- 4 codes that are covered (this list may not be all inclusive):

86003	Allergy specific IgE; quantitative or semiquantitative, crude allergen extract, each
86008	Allergen specific IgE; quantitative or semiquantitative, recombinant or purified component, each
95004	Percutaneous tests (scratch, puncture, prick) with allergenic extracts, immediate type reaction, including test interpretation and report, specify number of tests
95017	Allergy testing, any combination of percutaneous (scratch, puncture, prick) and intracutaneous (intra dermal), sequential and incremental, with venoms, immediate type reaction, including test interpretation and report, specify number of tests
95018	Allergy testing, any combination of percutaneous (scratch, puncture, prick) and intracutaneous (intra dermal), sequential and incremental, with drugs or biologicals, immediate type reaction, including test interpretation and report, specify number of tests
95024	Intracutaneous (intra dermal) tests with allergenic extracts, immediate type reaction, including test interpretation and report, specify number of tests
95027	Intracutaneous (intra dermal) tests, sequential and incremental, with allergenic extracts for airborne allergens, immediate type reaction including test interpretation and report, specify number of tests
95028	Intracutaneous (intra dermal) tests with allergenic extracts, delayed type reaction, including reading, specify number of tests
95044	Patch or application test(s) (specify number of tests)
95052	Photo patch test(s) (specify number of tests)
95115	Professional services for allergen immunotherapy not including provision of allergenic extracts; single injection
95117	Professional services for allergen immunotherapy not including provision of allergenic extracts; two or more injections
95144	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy; single dose vial(s) (specify number of vials)
95145	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); single stinging insect venom
95146	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 2 single stinging insect venoms
95147	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 3 single stinging insect venoms
95148	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 4 single stinging insect venoms
95149	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 5 single stinging insect venoms
95165	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy; single or multiple antigens (specify number of doses)
95170	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy; whole body extract of biting insect or other arthropod (specify number of doses)
95180	Rapid desensitization procedure, each hour (e.g., insulin, penicillin, equine serum)

Coding information is provided for informational purposes only. The inclusion or omission of a CPT, HCPCS, or ICD-10 code does not imply member coverage or provider reimbursement. Consult the member's benefits that are in place at time of service to determine coverage (or non-coverage) as well as applicable federal / state laws.

DEFINITIONS

Allergies	Also known as allergic diseases, are a number of conditions caused by hypersensitivity of the immune system to typically harmless substances in the environment. These diseases include hay fever, food allergies, atopic dermatitis, allergic asthma, and anaphylaxis.
Allergen	The substances that trigger allergy. Examples include pollens, dust mite, molds, danders, and certain foods.
Allergy testing	Also known as skin, prick or blood testing, is a method for determining to what substances a person is allergic.
Allergy skin testing	A test in which a small drop of the suspected allergy-provoking substance (allergen) is placed on the skin and the skin is then gently scratched through the drop with a sterile needle.
IgE (Immunoglobulin E) Antibodies	IgE Antibodies are a type of immunoglobulin made by the body which are implicated in allergic reactions.
Immunotherapy	Immunotherapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies
Radioallergosorbent (RAST)	A radioimmunoassay test used to detect specific IgE antibodies of suspected or known allergens for the purpose of determining an allergy diagnosis.

REFERENCES

1. Allergy facts and figures. Asthma and Allergy Foundation of America Website. <http://www.aafa.org/display.cfm?id=9&sub=30> Accessed September 19, 2019.
2. American Academy of Allergy, Asthma, and Immunology. "Five Things Physicians and Patients Should Question". Choosing Wisely: an initiative of the ABIM Foundation. Accessed September 19, 2019.
3. Billing and Coding Guidelines for Allergy Testing, LCD L36402. https://downloads.cms.gov/medicare-coverage-database/lcd_attachments/36402_2/L36402_ALRG004_BCG.pdf Accessed September 19, 2019.
4. Billing and Coding Guidelines for Allergy Testing. LCD L34597. 7. https://downloads.cms.gov/medicare-coverage-database/lcd_attachments/34597_9/L34597_ALRG001_BCG.pdf Accessed September 19, 2019.
5. Healthcentral Encyclopedia. "IgE Antibodies". <https://www.healthcentral.com/encyclopedia/ige-antibodies> Accessed September 19, 2019.

6. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma, and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2007;129:S25-85.
7. Medical Definition of Allergy. MedicineNet Website.
<https://www.medicinenet.com/script/main/art.asp?articlekey=2201> Accessed September 19, 2019.
8. Medical Definition of Allergy Skin Test. MedicineNet Website.
<https://www.medicinenet.com/script/main/art.asp?articlekey=2202> Accessed September 19, 2019.
9. United Healthcare Medical Policies. Allergy Testing.
<https://www.uhcprovider.com/content/dam/provider/docs/public/policies/lab-benefit-mgmt/UHC-LAB-Allergy-Testing-Policy.pdf>. Accessed September 19, 2019

IMPORTANT INFORMATION ABOUT THIS DOCUMENT

Claims and Payment Policies (CPPs) are policies regarding claims or claim line processing and/or reimbursement related to the administration of health plan benefits. They are not recommendations for treatment, nor should they be used as treatment guidelines. Providers are responsible for diagnosing, treating, and making clinical recommendations to the member. CPPs are subject to, but not limited to, the following:

- State and federal laws and regulations;
- Policies and procedures promulgated by the Centers for Medicare and Medicaid Services, including National Coverage Determinations and Local Coverage Determinations;
- The health plan's contract with Medicare and/or a state's Medicaid agency, as applicable;
- Other CPPs and clinical policies as applicable including, but not limited to, *Pre-Payment and Post-Payment Review*.
- The provisions of the contract between the provider and the health plan; and
- The terms of a member's particular benefit plan, including those terms outlined in the member's Evidence of Coverage, Certificate of Coverage, and other policy documents.

In the event of a conflict between a CPP and a member's policy documents, the terms of a member's benefit plan will always supersede the CPP.

The use of this policy is neither a guarantee of payment, nor a prediction of how a specific claim will be adjudicated. Any coding information is for informational purposes only. No inference should be made regarding coverage or provider reimbursement as a result of the inclusion, or omission, in a CPP of a CPT, HCPCS, or ICD-10 code. Always consult the member's benefits that are in place at time of service to determine coverage or non-coverage. Claims processing is subject to a number of factors, including the member's eligibility and benefit coverage on the date of service, coordination of benefits, referral/authorization requirements, utilization management protocols, and the health plan's policies. Services must be medically necessary in order to be covered.

References to other sources and links provided are for general informational purposes only, and were accurate at the time of publication. CPPs are reviewed annually but may change at any time and without notice, including the lines of business for which they apply. CPPs are available at www.wellcare.com. Select the "Provider" tab, then "Tools" and then "Payment Guidelines".

RULES, PRICING & PAYMENT COMMITTEE HISTORY AND REVISIONS

Date	Action
10/30/2019	<ul style="list-style-type: none"> • Approved by RGC